<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>Thrombosis Research via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Thrombosis Research' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Thrombosis+Research&t=Thrombosis+Research&s=Search&f=source]]></link>
        <lastBuildDate>Sat, 20 Mar 2010 14:25:18 +0100</lastBuildDate>
        <item>
            <title>A multicolor flow cytometric assay for measurement of platelet-derived microparticles</title>
            <link>http://www.medworm.com/index.php?rid=3308719&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004563%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: Flow cytometry (FCM) is the most commonly used method for detection of platelet-derived microparticles (PDMPs), but it is poorly standardized and mainly used for “bedside” analyses in fresh samples. If PDMPs could be analyzed in previously frozen samples it would increase the usefulness of the method. However, cell membrane fragments from contaminating cells created during freezing/thawing may cause artifacts and disturb measurements.Materials and Methods: PDMPs were labeled with monoclonal antibodies directed against CD42a and CD62P, or CD42a and CD142. The PDMP gate was determined using forward scatter (FSC) and CD42a expression. The mean fluorescence intensities (MFIs) of CD62P or CD142 positive particles were translated into MESF -values (Molecules of Equiva...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308719</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:50 +0100</pubDate>
            <guid isPermaLink="false">3308719</guid>        </item>
        <item>
            <title>Release of tissue-type plasminogen activator (t-PA) in the splanchnic circulation of the anaesthetised pig during high sympathetic tone</title>
            <link>http://www.medworm.com/index.php?rid=3308718&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900454X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Net splanchnic t-PA release increased only transiently during the period with increased sympathetic stimulation, whereas the arterial t-PA level remained elevated. During a strong and longlasting sympathetic stimulation the lack of a continuously augmented splanchnic t-PA release might increase the risk for intravenous splanchnic thrombosis. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308718</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:50 +0100</pubDate>
            <guid isPermaLink="false">3308718</guid>        </item>
        <item>
            <title>‘Pergularain e I’ – a plant cysteine protease with thrombin-like activity from Pergularia extensa latex</title>
            <link>http://www.medworm.com/index.php?rid=3308717&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004484%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Pergularain e I, a cysteine protease with thrombin-like activity, was purified by ion exchange chromatography from the latex of Pergularia extensa. Its homogeneity was characterized by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE), native PAGE and reverse-phase high-performance liquid chromatography (RP-HPLC). The molecular mass of pergularain e I by matrix-assisted laser desorption ionization–time of flight (MALDI–TOF) was found to be 23.356kDa and the N-terminal sequence is L–P–H–D–V–E. Pergularain e I is a glycoprotein containing ∼20% of carbohydrate. Pergularain e I constituted 6.7% of the total protein with a specific activity of 9.5 units/mg/min with a 2.11-fold increased purity. Proteolytic activity of the pergularain e I was comple...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308717</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:50 +0100</pubDate>
            <guid isPermaLink="false">3308717</guid>        </item>
        <item>
            <title>The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats</title>
            <link>http://www.medworm.com/index.php?rid=3308716&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004186%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: AZD6140 inhibits platelet reactivity in diabetic rats rapidly and reversibly. Markers of tonic platelet activation, which were increased in diabetic rats, were lowered to levels comparable to non-diabetic rats following chronic treatment with AZD6140. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308716</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:49 +0100</pubDate>
            <guid isPermaLink="false">3308716</guid>        </item>
        <item>
            <title>Homocysteine decreases extracellular nucleotide hydrolysis in rat platelets</title>
            <link>http://www.medworm.com/index.php?rid=3308715&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004137%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Hyperhomocysteinemia is an independent risk factor for atherothrombotic disease. Platelets play an important role in cardiovascular disease and release pro-aggregates mediators when activated, such as ADP, a physiological agonist involved in normal hemostasis and thrombosis. NTPDases and 5'-nucleotidase are ecto-enzymes that hydrolyze ATP, ADP and AMP to adenosine playing an important role on blood flow and thrombogenesis by regulating ADP catabolism. The aim of the present study was evaluate extracellular adenine nucleotide hydrolysis of rat platelets exposed to homocysteine in vitro and in vivo. In vitro homocysteine (Hcy) in the concentration range of 20 to 500μM caused a significant decrease on ATP (around 30%) and ADP (around 45%) hydrolysis, respectively, while AMP hydroly...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308715</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:49 +0100</pubDate>
            <guid isPermaLink="false">3308715</guid>        </item>
        <item>
            <title>Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism</title>
            <link>http://www.medworm.com/index.php?rid=3308714&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004101%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: In hemodynamically stable patients with PE, treatment with single bolus tenecteplase is feasible at the same dosages used for acute myocardial infarction and is associated with reduction of RVD at 24hours. Whether this benefit is associated with an improved clinical outcome without excessive bleeding is currently explored in a large clinical trial. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308714</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:48 +0100</pubDate>
            <guid isPermaLink="false">3308714</guid>        </item>
        <item>
            <title>Platelet activation and endogenous thrombin potential in pre-eclampsia</title>
            <link>http://www.medworm.com/index.php?rid=3308713&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900406X%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: Platelets and the coagulation system may be involved in the pathogenesis of pre-eclampsia. We investigated whether platelet and coagulation activation markers, are elevated in pre-eclampsia.Materials/methods: Case-control study in which activated platelets, platelet-monocyte/ neutrophil aggregates, platelet microparticles (measured by flow cytometry) and four markers of thrombin generation capacity (endogenous thrombin potential (ETP), peak height, lag time and time to peak) using the Calibrated Automated Thrombogram system were assessed in pregnant women of similar gestational age with (n=46) and without (n=46) pre-eclampsia, and in healthy non-pregnant women (n=42).Results: The percentage of, CD62P+ platelets (p=0.013), CD62P+ platelet microparticles (p=0.029) and...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308713</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:48 +0100</pubDate>
            <guid isPermaLink="false">3308713</guid>        </item>
        <item>
            <title>Expression of protein C (PC), protein S (PS) and thrombomodulin (TM) in human colorectal cancer</title>
            <link>http://www.medworm.com/index.php?rid=3308712&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004046%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: Heterogeneous expression of the PC system components in CRC tissue may point to their biological activity modulating tumor growth. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308712</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:47 +0100</pubDate>
            <guid isPermaLink="false">3308712</guid>        </item>
        <item>
            <title>Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: Results from a multicenter, randomized, open-label study</title>
            <link>http://www.medworm.com/index.php?rid=3308711&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004022%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: These favorable efficacy and safety data support the use of enoxaparin (20mg twice daily for 14days started 24–36hours after surgery) in Japanese patients undergoing abdominal or pelvic cancer surgery. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308711</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:47 +0100</pubDate>
            <guid isPermaLink="false">3308711</guid>        </item>
        <item>
            <title>Prothrombinase formation at the site of microvascular injury and aspirin resistance: The effect of simvastatin</title>
            <link>http://www.medworm.com/index.php?rid=3308710&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809005672%2Fabstract%3Frss%3Dyes</link>
            <description>The production of thrombin is determined by the formation of the prothrombinase complex, which assembles predominantly on activated platelets. Aspirin that suppresses the synthesis of thromboxane A2 (TXA2) has been shown to reduce thrombin formation at the site of injury . We have reported that impaired platelet sensitivity to aspirin, called aspirin resistance, is associated with faster thrombin generation following injury . (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308710</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:47 +0100</pubDate>
            <guid isPermaLink="false">3308710</guid>        </item>
        <item>
            <title>Increased thrombin generation in inflammatory bowel diseases</title>
            <link>http://www.medworm.com/index.php?rid=3308709&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004897%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Background: Inflammatory bowel diseases (IBD) are characterized by an increased thrombotic risk of uncertain etiology. Endogenous thrombin potential (ETP), a parameter of the thrombin generation curve, represents a new tool in the evaluation of thrombotic and bleeding disorders.Aims: To study ETP in IBD patients and to correlate the results with clinical and biochemical features.Methods: Seventy-four IBD patients (37 ulcerative colitis and 37 Crohn's disease) and 74 sex- and age-matched healthy individuals. ETP was measured upon activation of coagulation with small amounts of tissue factor and phospholipids in the presence or absence of thrombomodulin; results were expressed as nM thrombin·minutes.Results: Mean±SD ETP values were significantly higher in patients (1,499±454) th...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308709</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:47 +0100</pubDate>
            <guid isPermaLink="false">3308709</guid>        </item>
        <item>
            <title>Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model</title>
            <link>http://www.medworm.com/index.php?rid=3308708&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004885%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: In an animal model of dilutional coagulopathy and kidney trauma, PCC accelerated hemostasis and diminished blood loss compared with rFVIIa monotherapy. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308708</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:47 +0100</pubDate>
            <guid isPermaLink="false">3308708</guid>        </item>
        <item>
            <title>Markers of haemostasis and angiogenesis in placentae from gestational vascular complications: Impairment of mechanisms involved in maintaining intervillous blood flow</title>
            <link>http://www.medworm.com/index.php?rid=3308707&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004174%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Haemostasis factors are reduced in placentae from complicated pregnancies. The relationship between haemostasis and angiogenesis observed in uncomplicated pregnancies is impaired in PE and FGR. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308707</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:47 +0100</pubDate>
            <guid isPermaLink="false">3308707</guid>        </item>
        <item>
            <title>Impaired secretion of carboxyl-terminal truncated factor VII due to an F7 nonsense mutation associated with FVII deficiency</title>
            <link>http://www.medworm.com/index.php?rid=3308706&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004071%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The carboxyl-terminal amino acids of FVII play an important role in its secretion, and the p.Arg462X mutation was likely to have caused the FVII deficiency in this patient. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308706</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:46 +0100</pubDate>
            <guid isPermaLink="false">3308706</guid>        </item>
        <item>
            <title>PAR1 antagonist mediated antithrombotic activity in extracorporeal arterio-venous shunt in the rat</title>
            <link>http://www.medworm.com/index.php?rid=3308705&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002199%2Fabstract%3Frss%3Dyes</link>
            <description>The activation of platelets by thrombin is mediated at least in part by cleavage of protease-activated receptors (PARs) . Four distinct PARs have been cloned to date, with PAR1, PAR3 and PAR4 being activated by thrombin, whereas PAR2 is sensitive to trypsin . Human platelets express PAR1 and PAR4 and activation of either is sufficient to trigger platelet aggregation and secretion . Studies with selective neutralizing antibodies have indicated that PAR1 mediates activation of human platelets at low thrombin concentrations and that, in the absence of PAR1 function, PAR4 can mediate platelet activation but only at high thrombin concentrations . Curiously, PAR1 appears not to play a role in rat platelets. PAR1-activating peptides do not activate rat platelet aggregation . In contrast to this, ...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308705</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:46 +0100</pubDate>
            <guid isPermaLink="false">3308705</guid>        </item>
        <item>
            <title>Presence of Integrin alpha(IIb)beta3 in early gestation human trophoblasts: Possible involvement of fibrin as a matrix ligand</title>
            <link>http://www.medworm.com/index.php?rid=3308704&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809005350%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Our finding demonstrate the transient presence and participation of αIIbβ3 in the orchestrated adhesion molecules of trophblasts and villi. The increased adhesion and expression of αIIb in trophoblasts on fibrin suggest its involvement as a ligand in the extracellular milieu of the early fetal placenta. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308704</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:46 +0100</pubDate>
            <guid isPermaLink="false">3308704</guid>        </item>
        <item>
            <title>The effect of the long term aspirin administration on the progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse</title>
            <link>http://www.medworm.com/index.php?rid=3308703&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900509X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: Our results suggest that endothelial dysfunction with low dose aspirin improved, reduced progression of atherosclerosis in apoE-/- and LDLR-/- double deficient mice and provides a pathophysiological basis for the beneficial effects of aspirin in atherosclerosis, and low doses appeared to be more efficient than high doses. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308703</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:46 +0100</pubDate>
            <guid isPermaLink="false">3308703</guid>        </item>
        <item>
            <title>Flow-based measurements of von Willebrand factor (VWF) function: Binding to collagen and platelet adhesion under physiological shear rate</title>
            <link>http://www.medworm.com/index.php?rid=3308702&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900396X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The established flow-chamber model represents an easy-to-set-up and customized tool for the characterization of VWF-binding to collagen as well as the determination of VWF-dependent platelet adhesion under defined flow conditions in real-time. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308702</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:46 +0100</pubDate>
            <guid isPermaLink="false">3308702</guid>        </item>
        <item>
            <title>Prophylactic plasma levels of the low molecular weight heparin nadroparin does not affect colon cancer tumor development in mouse liver</title>
            <link>http://www.medworm.com/index.php?rid=3308701&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001273%2Fabstract%3Frss%3Dyes</link>
            <description>Clinical trials showed life-prolonging effects of low molecular weight heparins (LMWHs) in cancer patients with and without thrombotic complications . An inhibitory effect of anticoagulants on metastasis has been found in animal studies, usually in the mouse model of B16 melanoma tumor development in lung . In this model, anticoagulants have effects only when administered at the time of cancer cell inoculation . The effects are exerted by blocking P- and L- selectins thus inhibiting interactions between cancer cells and endothelium either or not in combination with heparanase inhibition . (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308701</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:45 +0100</pubDate>
            <guid isPermaLink="false">3308701</guid>        </item>
        <item>
            <title>Hereditary protein C deficiency caused by the Ala267Thr mutation in the protein C gene is associated with symptomatic and asymptomatic venous thrombosis</title>
            <link>http://www.medworm.com/index.php?rid=3308700&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002485%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: Protein C (PC) is a key anticoagulant that regulates hemostasis, and inherited deficiency of PC is an established risk factor for venous thrombosis (VT). The factor V Leiden mutation causing activated PC (APC) resistance is an additional risk factor for VT. Reduced PC levels in the circulation and/or APC resistance do not necessarily lead to thrombotic disease. In the present study we describe and characterize an ethnic Lebanese family in which individuals with reduced PC levels and APC resistance have various clinical symptoms.Methods: PC activity and antigen levels and APC resistance in the family members were quantified with commercial kits. Sequencing of PC DNA and mRNA was performed with BigDye Terminator Cycle Sequencing kit on the ABI 3730 Genetic Analyzer.Re...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308700</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:45 +0100</pubDate>
            <guid isPermaLink="false">3308700</guid>        </item>
        <item>
            <title>Decreasing warfarin sensitivity during the first three months after heart valve surgery: Implications for dosing</title>
            <link>http://www.medworm.com/index.php?rid=3308699&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001224%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Patients steadily become less sensitive to warfarin during the first months after heart valve surgery. This leads to subtherapeutic anticoagulation. A dosing algorithm that takes increasing requirements into account is proposed. This algorithm will need to be validated prospectively. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308699</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:45 +0100</pubDate>
            <guid isPermaLink="false">3308699</guid>        </item>
        <item>
            <title>Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients</title>
            <link>http://www.medworm.com/index.php?rid=3308698&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900098X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Overall, 46% of patients were female, the average age (±SD) was 54 (±11) years, and the average weight and BMI were 135.6 kg (±25.3) and 48.1 kg/m2 (±11.1), respectively. The average daily dose of enoxaparin was 67 mg (±12). The average peak anti-Xa level was 0.25 (SD±0.11, range 0.08 to 0.59) units/mL. Peak anti-Xa levels did not significantly correlate with weight or BMI. There were no bleeding events, symptomatic VTE, or significant thrombocytopenia.In morbidly obese, medically-ill patients, use of weight-based enoxaparin dosed at 0.5 mg/kg once daily is feasible and results in peak anti-Xa levels within or near recommended range for thromboprophylaxis, without any evidence of excessive anti-Xa activity. These data suggest that this weight-based regimen may be mor...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308698</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:45 +0100</pubDate>
            <guid isPermaLink="false">3308698</guid>        </item>
        <item>
            <title>The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease</title>
            <link>http://www.medworm.com/index.php?rid=3308697&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809000267%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: Monoclonal gammopathy of undetermined significance (MGUS) has been proposed to be a risk factor for venous thromboembolic disease (VTE). However, no series published to date has been population-based or included a control group with similar comorbidities to people with MGUS.Patients/Methods: We reviewed the records of all the male veterans in a single VA healthcare system with MGUS between January 1, 1996 and December 31, 2005. We compared the rate of VTE in 166 patients with MGUS with the rate of VTE in an age-matched control group of 465 patients who had tested negative for monoclonal gammopathy by serum protein electrophoresis (SPEP).Results: The VTE rate in the MGUS group was 2.2 per 100 person-years, which was not significantly different from the rate in the co...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308697</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:45 +0100</pubDate>
            <guid isPermaLink="false">3308697</guid>        </item>
        <item>
            <title>Factor XII: What does it contribute to our understanding of the physiology and pathophysiology of hemostasis &amp; thrombosis</title>
            <link>http://www.medworm.com/index.php?rid=3308696&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809005416%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Factor XII (FXII) is a coagulation protein that is essential for surface-activated blood coagulation tests but whose deficiency is not associated with bleeding. For over forty years, investigators in hemostasis have not considered FXII important because its deficiency is not associated with bleeding. It is because there is a dichotomy between abnormal laboratory assay findings due to FXII deficiency and clinical hemostasis that investigators sought explanations for physiologic hemostasis independent of FXII. FXII is a multidomain protein that contains two fibronectin binding consensual sequences, two epidermal growth factor regions, a kringle region, a proline-rich domain, and a catalytic domain that when proteolyzed turns into a plasma serine protease. Recent investigations with...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308696</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:45 +0100</pubDate>
            <guid isPermaLink="false">3308696</guid>        </item>
        <item>
            <title>The role of inflammation in regulating platelet production and function: Toll-like receptors in platelets and megakaryocytes</title>
            <link>http://www.medworm.com/index.php?rid=3308695&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809005040%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Platelets have been extensively studied as hemostatic regulators, stopping uncontrolled flow of blood from an injured vessel and allowing for repair. However, multiple studies have shown that platelets can interact with bacterial proteins, particularly seen during sepsis and inflammation. Immune cells recognize pathogens through Toll-like Receptors (TLRs). These same receptors allow platelets to recognize bacterial proteins and regulate platelet immunity and function. This review examines the TLRs expressed on platelets and megakaryocytes and how these receptors affect the function of these cells. Through TLRs, platelets go beyond hemostatic regulation and play a pivotal role in inflammation and infection. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308695</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:45 +0100</pubDate>
            <guid isPermaLink="false">3308695</guid>        </item>
        <item>
            <title>“Coagulation Proteins with Uncertain Function”</title>
            <link>http://www.medworm.com/index.php?rid=3308694&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384810000447%2Fabstract%3Frss%3Dyes</link>
            <description>“To raise new questions, new possibilities, to regard old problems from a new angle, requires creative imagination and marks real advance in science.” Albert Einstein (1879-1955) (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308694</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:45 +0100</pubDate>
            <guid isPermaLink="false">3308694</guid>        </item>
        <item>
            <title>Editorial Board</title>
            <link>http://www.medworm.com/index.php?rid=3308693&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384810001398%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308693</comments>
            <pubDate>Fri, 26 Feb 2010 14:24:45 +0100</pubDate>
            <guid isPermaLink="false">3308693</guid>        </item>
        <item>
            <title>Platelet glycoprotein GP VI 13254C allele is an independent risk factor of premature myocardial infarction</title>
            <link>http://www.medworm.com/index.php?rid=3285509&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003934%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The presence of the GP VI 13254C allele is an independent predictor of premature MI. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285509</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285509</guid>        </item>
        <item>
            <title>Combined cis-regulator elements as important mechanism affecting FXII plasma levels</title>
            <link>http://www.medworm.com/index.php?rid=3285508&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003922%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: We have identified two naturally-occurring mutations in the F12 promoter that drastically reduce FXII levels. Knowing rare genetic alterations in the F12 gene, together with the C46T common variant, may yield further understanding about the genetic architecture of FXII levels, which may have a role in the risk of thrombosis. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285508</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285508</guid>        </item>
        <item>
            <title>Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy</title>
            <link>http://www.medworm.com/index.php?rid=3285507&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003880%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: Currently, there is an intense debate about whether comedication with proton pump inhibitors (PPIs) weakens the antiplatelet effect of clopidogrel in patients undergoing coronary stent implantation. Competing mechanisms on the hepatic cytochrome 2C19 level are proposed. The aim of this study was to assess the impact of PPI treatment on clopidogrel response by measuring the ex vivo platelet aggregation in patients with coronary intervention.Methods: 1425 consecutive patients with symptomatic coronary artery disease undergoing percutaneous coronary intervention were enrolled in this single centre study. PPI comedication was defined as PPI intake ≥1 week prior to a 600 mg clopidogrel loading dose. PPI treatment was based on physician preference. Residual platelet a...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285507</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285507</guid>        </item>
        <item>
            <title>Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure - a COMET substudy</title>
            <link>http://www.medworm.com/index.php?rid=3285506&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003478%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: We found no significant difference in the effects of carvedilol or metoprolol on tPA, PAI-1 and VWF. Comparison over time within treatment groups suggested that PAI-1 and VWF might have declined on carvedilol but not on metoprolol. Our hypothesis is not proved but this may reflect an inadequate sample size rather than lack of an effect. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285506</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285506</guid>        </item>
        <item>
            <title>Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients</title>
            <link>http://www.medworm.com/index.php?rid=3285505&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003466%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The present study suggests a relationship between kynurenine pathway of tryptophan degradation, haemostatic and biochemical disturbances and CVD prevalence in peritoneally dialyzed patients. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285505</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285505</guid>        </item>
        <item>
            <title>Membrane binding and anticoagulant properties of protein S natural variants</title>
            <link>http://www.medworm.com/index.php?rid=3285504&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004083%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: Protein S (PS) is a vitamin K-dependent plasma glycoprotein with a key role in the control of coagulation pathway on phospholipid membranes. We compared anticoagulant and membrane binding properties of PS altered by natural mutations (N217S, DelI203D204) affecting the epidermal growth factor like-domain 4 (EGF4) and causing PS deficiency.Materials and methods: Binding of recombinant, immunopurified PS (rPS) to several conformation-specific antibodies, to C4BP and to phospholipid liposomes was investigated by ELISA. PS binding to cells was analysed by flow cytometry. PS inhibitory activities were studied in plasma and purified systems.Results and conclusions: Conformational changes produced by mutations were revealed by mapping with calcium-dependent antibodies. The ...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285504</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285504</guid>        </item>
        <item>
            <title>Role of NMDA receptor in homocysteine-induced activation of Mitogen-Activated Protein Kinase and Phosphatidyl Inositol 3-Kinase pathways in cultured human vascular smooth muscle cells</title>
            <link>http://www.medworm.com/index.php?rid=3285503&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003867%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: Exposure of vascular smooth muscle cells (VSMC) to homocysteine, at concentrations associated with an increased risk of cardiovascular events, enhances synthesis and secretion of Matrix Metalloproteinase-2 (MMP-2), which is involved in atherosclerotic plaque instabilization. This effect was prevented by inhibitors of Mitogen Activated Protein Kinase (MAPK) and Phosphatidylinositol 3-Kinase (PI3-K) pathways, allowing to hypothesize that homocysteine activates both these pathways, likely via a receptor-mediated mechanism. One possible receptor is N-methyl-D-aspartate receptor (NMDAr), which is expressed in VSMC and is involved in homocysteine effects in other cell types.Materials and Methods: VSMC exposed to DL-homocysteine or NMDA (100 μmol/L for both; 5 min-8 ho...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285503</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285503</guid>        </item>
        <item>
            <title>A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers</title>
            <link>http://www.medworm.com/index.php?rid=3285502&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900348X%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: In type 2B von Willebrand disease (2B VWD), abnormal von Willebrand factor (VWF) spontaneously binds to platelets. This leads to the clearance of the high molecular weight multimers (HMWM) of VWF and results in thrombocytopenia. Herein we report a family of 2B VWD with an R1306W mutation which caused thrombocytopenia with giant platelets. The most important finding in this study is dynamic changes in VWF values in association with platelet counts. When the proband (2years of age) had severe thrombocytopenia, his HMWM were normal, however, hematological examination showed a low level of VWF and a lack of HMWM after platelet count recovered. His affected sister also exhibited similar phenomenona. These results suggest that the severe thrombocytopenia leads to decreased clearance of...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285502</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285502</guid>        </item>
        <item>
            <title>Protein C deficiency in Thai children with thromboembolism: A report of clinical presentations and mutation analysis</title>
            <link>http://www.medworm.com/index.php?rid=3285501&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004939%2Fabstract%3Frss%3Dyes</link>
            <description>Protein C, a natural anticoagulant, has been reported to be a common thrombophilic risk factor in Thai and other Asian populations . Patients with protein C deficiency mainly present with venous rather than arterial thromboembolism . (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285501</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285501</guid>        </item>
        <item>
            <title>Gamma tocopherol supplementation prevents exercise induced coagulation and platelet aggregation</title>
            <link>http://www.medworm.com/index.php?rid=3285500&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809005167%2Fabstract%3Frss%3Dyes</link>
            <description>Bouts of strenuous exercise in sedentary individuals acutely increases cardiovascular risk with a 100 fold increased risk of myocardial infarction immediately following exercise and 40% of all patients who experience myocardial infarction reporting physical activity as the trigger. Acute strenuous exercise is associated with increased coagulation and platelet aggregation , which are likely to be contributing factors to the associated acute atherothrombotic risk. The mechanism(s) by which these parameters of haemostasis are affected by exercise are multifactorial and include increased platelet and coagulation factor concentration associated with dehydration and splenic or hepatic release as well as enhanced activation of platelets by adrenaline and oxidative stress through increased generat...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285500</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285500</guid>        </item>
        <item>
            <title>Accuracy of a portable international normalized ratio monitor for patients receiving a low molecular weight heparin as a bridge pending full oral anticoagulant efficacy</title>
            <link>http://www.medworm.com/index.php?rid=3285499&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003958%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Background: Point of care (POC) devices measuring the international normalized ratio (INR) are accurate for patients with stable disease, but their efficiency has not been prospectively assessed during the “bridging period” when patients are receiving a low molecular weight heparin (LMWH) on top of a vitamin K antagonist (VKA) until the target INR is reached.Methods: 188 dual INR measurement using the POC (INRPOC) and the laboratory (INRlab) at the same time were consecutively determined : 69 in patients receiving LMWH+VKA (bridging group) and 119 in patients receiving only a VKA (control group). INRpoc was compared to INRlab.Results: Test strip failure rate was higher in the bridging group than in the control group (29% vs 4% ; p (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285499</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285499</guid>        </item>
        <item>
            <title>Activated protein C stimulates osteoblast proliferation via endothelial protein C receptor</title>
            <link>http://www.medworm.com/index.php?rid=3285498&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003983%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: APC stimulates osteoblast proliferation by activating p44/42 MAP kinase through a mechanism that requires EPCR but not PAR-1 or the proteolytic activity of APC. APC generated at fracture sites may contribute to fracture healing by promoting osteoblast proliferation. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285498</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285498</guid>        </item>
        <item>
            <title>Daunorubicin induces procoagulant response through phosphatidylserine exposure in red blood cells</title>
            <link>http://www.medworm.com/index.php?rid=3285497&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003995%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: We conclude that daunorubicin interacts with red blood cells in a manner that increases phosphatidylserine exposure and consequent procoagulant activity. Lactadherin is an efficient anticoagulant of this process. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285497</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285497</guid>        </item>
        <item>
            <title>Coagulation activation and ultrasound characteristics in patients with carotid artery disease</title>
            <link>http://www.medworm.com/index.php?rid=3285496&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003879%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Patients with carotid artery disease exhibit increased concentrations of APC-PCI compared to a healthy control-group, particularly those patients with echogenic plaques, who have significantly higher APC-PCI levels than patients with echolucent plaques. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285496</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285496</guid>        </item>
        <item>
            <title>Hospital mortality due to pulmonary embolism and an evaluation of the usefulness of preventative interventions</title>
            <link>http://www.medworm.com/index.php?rid=3285495&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003120%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: Hospital mortality due to clinically recognized PE can be determined by chart review of PE cases identified using the ICD coding system. Death due to PE is often potentially preventable; in the subgroup with cancer and DVT/PE, an IVCF may be a potentially useful intervention to prevent death due to PE. Prospective studies are needed to confirm these results. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285495</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285495</guid>        </item>
        <item>
            <title>Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors</title>
            <link>http://www.medworm.com/index.php?rid=3285494&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809005076%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: Ap4A, a constituent of platelet dense granules, is a) an antagonist of platelet P2Y1 and P2Y12 receptors, where it inhibits the effects of ADP, and b) an agonist of platelet P2X1 and P2Y12 receptors. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285494</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285494</guid>        </item>
        <item>
            <title>Palmitoylation supports the association of tetraspanin CD63 with CD9 and integrin αIIbβ3 in activated platelets</title>
            <link>http://www.medworm.com/index.php?rid=3285493&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003235%2Fabstract%3Frss%3Dyes</link>
            <description>This study investigated the role of palmitoylation in platelet TEM assembly and maintenance. [3H]-palmitate-labeled, washed human platelets were studied at rest, or following activation with thrombin (0.1 U/ml). CD63 and CD9 were separated by density gradient centrifugation, isolated by immunoprecipitation, and [3H]-palmitate was measured in each fraction. Palmitate levels increased in all fractions following thrombin activation. However, the relative inter-fraction distribution of the tetraspanins did not change. 2-bromopalmitate (2-BP), an inhibitor of protein palmitoylation as demonstrated by decreased [3H]-palmitate labeling of platelet proteins, blocked both thrombin-induced platelet aggregation and platelet spreading on immobilized fibrinogen in a dose-dependent manner. 2-BP also in...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285493</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285493</guid>        </item>
        <item>
            <title>Cyclic nucleotides inhibit MAP kinase activity in low-dose collagen-stimulated platelets</title>
            <link>http://www.medworm.com/index.php?rid=3285492&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002709%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Collagen-induced platelet activation is a complex process involving multiple signaling pathways. The role(s) of MAP kinases (ERKs and p38MAPK) are unclear, although at high, but not low, collagen concentrations p38MAPK is involved in cPLA2-mediated arachidonic acid release, prior to thromboxane generation. Cyclic nucleotides are conventionally regarded as mediators of platelet inhibition. However recent studies suggested a role for cGMP early in a MAP kinase pathway in platelet activation. In the current study the roles and relationships of MAP kinases, cyclic nucleotides and cPLA2 in platelet activation by low-dose collagen and a thromboxane analogue (U46619) have been evaluated. Stimulants of neither adenylate cyclase (PGI2) nor guanylate cyclase (NaNP) alone had any effect on ...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285492</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285492</guid>        </item>
        <item>
            <title>The role of the Platelet Function Analyzer (PFA)-100 and platelet aggregometry in the differentiation of essential thrombocythemia from reactive thrombocytosis</title>
            <link>http://www.medworm.com/index.php?rid=3285491&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003181%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: If our results are replicated by further studies, these two methods could be used very effectively as adjunct markers in the differentiation between ET and RT. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285491</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285491</guid>        </item>
        <item>
            <title>Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study</title>
            <link>http://www.medworm.com/index.php?rid=3285490&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002229%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Parnaparin appears to be more effective than aspirin in preventing functional worsening in patients with RVO. The results of this study need to be confirmed in a larger clinical trial.Trial registration number: Clinical trials.gov NCT00732927. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285490</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285490</guid>        </item>
        <item>
            <title>Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice</title>
            <link>http://www.medworm.com/index.php?rid=3285489&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002230%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The diagnostic approach to VTE among expert physicians appears to be heterogeneous; in particular there is no widespread use of clinical prediction rules. The majority of expert physicians appear to consider the possibility of treating at home patients with PE. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285489</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285489</guid>        </item>
        <item>
            <title>Low level of factor V is associated with development of deep-vein thrombosis in Japanese patients</title>
            <link>http://www.medworm.com/index.php?rid=3285488&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002254%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Background: Factor V, having two functions (procoagulant and anticoagulant), is a key factor in blood coagulation, and low plasma levels of factor V may be a risk factor for thrombosis.Objective: The levels of plasma factor V antigen (FV:Ag), and the phospholipid binding capability of Factor V (FV:PL-bound) were evaluated in patients with deep-vein thrombosis (DVT).Methods: Levels of FV:Ag, and FV:PL-bound were expressed as a percentage of the normal level found in pooled plasma from control subjects. One hundred and twenty-three Japanese patients with deep-vein thrombosis (DVT) were included, with 100 age and sex-matched healthy control subjects.Results: The FV:Ag, and FV:PL-bound values were significantly lower in DVT patients than in healthy subjects (p (Source: Thrombosis Res...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285488</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285488</guid>        </item>
        <item>
            <title>Primary atherothrombotic occlusive vascular events in premenopausal women with history of adverse pregnancy outcome</title>
            <link>http://www.medworm.com/index.php?rid=3285487&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002588%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: IUGR and composite pregnancy complications are independent significant variables associated with AOVD in premenopausal period. Pregnancy outcome might serve as a means to identify patients who may require increased medical surveillance and preventive measures for later vascular disease. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285487</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285487</guid>        </item>
        <item>
            <title>Factor V Leiden and hemophilia</title>
            <link>http://www.medworm.com/index.php?rid=3285486&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809005039%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Several inherited prothrombotic risk factors have been identified so far. Among them, the factor V (FV) Leiden mutation causes a reduced ability of activated protein C to inactivate activated FV and is the most frequent genetic predisposing factor for venous thromboembolism. However, the high prevalence of FV Leiden (up to 15%) in the Caucasian population suggests that this mutation might confer an evolutionary survival advantage. Indeed, there is mounting evidence about the role of FV Leiden in modulating the clinical phenotype of some physiological and pathological conditions, including hemophilia. The existing literature on the interaction between FV Leiden and hemophilia-related factor VIII or IX mutations is analyzed in this review focusing on the clinical effects and possib...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285486</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285486</guid>        </item>
        <item>
            <title>Cardiovascular complications of diabetes mellitus: The Tissue Factor perspective</title>
            <link>http://www.medworm.com/index.php?rid=3285485&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003193%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Heightened activity of circulating Tissue Factor (TF) has been linked to a variety of macro- and microvascular cardiovascular complications commonly observed in diabetes mellitus. Systemic and localized vascular abnormalities comprise the most debilitating feature of diabetic pathophysiology. Blood monocytes are chronically activated in diabetes, and serve as the major source of bioactive intravascular TF. This review examines recent literature on this subject, with a special emphasis on the abnormal monocyte physiology in diabetes and the structural and functional diversity of circulating TF. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285485</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285485</guid>        </item>
        <item>
            <title>Clopidogrel and proton pump inhibitors: Are the goal posts shifting?</title>
            <link>http://www.medworm.com/index.php?rid=3285484&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809005155%2Fabstract%3Frss%3Dyes</link>
            <description>Modern treatment of acute coronary syndrome involves reducing platelet activity. Currently this is achieved orally by generally targeting 2 pathways of platelet activation, the cyclooxygenase pathway, with aspirin and the ADP receptor, most commonly with clopidogrel. This leads to a reduction in death from cardiovascular causes, non fatal myocardial infarction and stroke in both patients treated with medical therapy and in those undergoing percutaneous coronary angioplasty . Any impact of reducing the efficacy of such antiplatelet therapies may lead to potentially worse outcomes in coronary patients. Therefore any drug-drug interaction that impairs antiplatelet drug efficacy should be avoided. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285484</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285484</guid>        </item>
        <item>
            <title>Pathology, imaging and treatment of cardiac microvascular obstruction</title>
            <link>http://www.medworm.com/index.php?rid=3285483&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003168%2Fabstract%3Frss%3Dyes</link>
            <description>It has been known since the mid-1970s that tissue perfusion can remain impaired after myocardial infarction, even after restoration of epicardial blood flow . The cause of this ‘no reflow’ phenomenon is multifactorial. Damage to the endothelium occurs after prolonged ischaemia . Kloner et al showed that interruption of blood flow in a coronary artery lasting 40 minutes resulted in myocardial death but did not cause irreversible endothelial damage . However, coronary occlusion lasting more than 90 minutes resulted in visible endothelial damage. Reperfusion of regions where there is endothelial damage could result in plugging of the microcirculation by red blood cells and thrombi . Activation of leukocytes, particularly neutrophils, results in the adhesion of these cells to the vessel ...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285483</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285483</guid>        </item>
        <item>
            <title>Why do we want to know how factor XII levels are modulated?</title>
            <link>http://www.medworm.com/index.php?rid=3285482&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004162%2Fabstract%3Frss%3Dyes</link>
            <description>New interest in factor XII has been found due to the fact that its murine knockout animal is protected from arterial thrombosis in several models . The mechanism(s) for these observations have not been precisely described. However, several investigators have shown that factor XII converting to factor XIIa presumably by autoactivation on surfaces such as platelet polysomes, expressed RNA, exposed vascular collagen, and/or aggregated protein contributes to developing thrombus . Since factor XII participates in the size of an induced-clot formation it has a role in thrombosis. This activity describes for the first time an in vivo pathophysiologic event contributed to by factor XII/XIIa. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285482</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285482</guid>        </item>
        <item>
            <title>Editorial Board</title>
            <link>http://www.medworm.com/index.php?rid=3285481&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384810000654%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3285481</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3285481</guid>        </item>
        <item>
            <title>The DD genotype of the angiotensin converting enzyme gene independently associates with CMR-derived abnormal microvascular perfusion in patients with a first anterior ST-segment elevation myocardial infarction treated with thrombolytic agents</title>
            <link>http://www.medworm.com/index.php?rid=3016307&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003296%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The DD genotype associates to a higher risk of abnormal microvascular perfusion after STEMI. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016307</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:53 +0100</pubDate>
            <guid isPermaLink="false">3016307</guid>        </item>
        <item>
            <title>In retinal vein occlusion platelet response to thrombin is increased</title>
            <link>http://www.medworm.com/index.php?rid=3016306&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003302%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Altogether data suggest that platelet hyperaggregability inducing thrombus formation might be an important factor in the onset and/or development of retinal vein occlusion. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016306</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:53 +0100</pubDate>
            <guid isPermaLink="false">3016306</guid>        </item>
        <item>
            <title>Use of recombinant activated factor VII in severe post-partum haemorrhage: Data from the Italian Registry: A multicentric observational retrospective study</title>
            <link>http://www.medworm.com/index.php?rid=3016305&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003910%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Purpose: To report the Italian real experience in clinical practice about recombinant factor VII activated (rFVIIa) in Post-Partum Haemorrhage (PPH) treatment.Methods: An Italian retrospective survey of severe primary PPH cases treated with rFVIIa was performed. Anamnestic, clinical and haemostatic data about thirty-five patients with PPH, from 2005 to 2007, were collected. Coagulative parameters and transfusion requirements before and after rFVIIa treatment were compared.Results: After rFVIIa administration INR was significantly decreased, while fibrinogen levels were markedly increased. Median of packed red blood cells units, platelets units, fresh frozen plasma, crystalloids and colloids needed, before and after rFVIIa administration, were respectively 6 and 2 units (p (Source...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016305</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:53 +0100</pubDate>
            <guid isPermaLink="false">3016305</guid>        </item>
        <item>
            <title>Antiplatelet effects of n-3 polyunsaturated fatty acids compared with aspirin: A pilot study with whole-blood aggregometry</title>
            <link>http://www.medworm.com/index.php?rid=3016304&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002072%2Fabstract%3Frss%3Dyes</link>
            <description>n-3 polyunsaturated fatty acids (n-3 PUFAs) are believed to play a cardioprotective role. Low blood levels of PUFAs may increase the risk of acute coronary syndrome . According to the GISSI-P study, PUFAs reduce mortality in patients after myocardial infarction and are recommended in secondary prevention after myocardial infarction . Moreover, PUFAs decrease mortality and frequency of hospitalisation for cardiovascular reasons in patients with heart failure . The beneficial effects of PUFAs are possibly associated with their pleiotropic mechanisms of action. One mechanism may be the anticoagulatory potential . However, the exact mechanisms are still unclear. Therefore, the goal of our present clinical trial was to assess a possible effect of treatment with PUFAs on platelet aggregation by ...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016304</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:52 +0100</pubDate>
            <guid isPermaLink="false">3016304</guid>        </item>
        <item>
            <title>Effect of capsaicin and dihydrocapsaicin on in vitro blood coagulation and platelet aggregation</title>
            <link>http://www.medworm.com/index.php?rid=3016303&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002138%2Fabstract%3Frss%3Dyes</link>
            <description>Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in developed countries. The growing clinical and financial burden of CVD is, at least in part, being driven by aging populations, and thus represents a significant challenge to health care systems with regard to diagnosis, prevention and treatment. Novel cost-effective approaches that slow or prevent the onset and/or reduce the incidence of CVD warrant investigation. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016303</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:52 +0100</pubDate>
            <guid isPermaLink="false">3016303</guid>        </item>
        <item>
            <title>The effects of twelve representative flavonoids on tissue factor expression in human monocytes: Structure-activity relationships</title>
            <link>http://www.medworm.com/index.php?rid=3016302&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002035%2Fabstract%3Frss%3Dyes</link>
            <description>Flavonoids are polyphenolic compounds found in numerous plant foods, including fruits, vegetables, tea, wine, nuts, seeds, herbs and spices . Epidemiological and experimental evidence suggests a relationship between consumption of foods rich in flavonoids and a reduced risk of cardiovascular disease (CVD) . Some flavonoids are hypothesized to possess anti-inflammatory properties, improve endothelial function, and inhibit platelet aggregation . However, in-depth knowledge on whether and how flavonoids protect against heart disease is lacking. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016302</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:52 +0100</pubDate>
            <guid isPermaLink="false">3016302</guid>        </item>
        <item>
            <title>Lack of change in insulin levels as a biological marker of PAI-1 lowering in GH-deficient adults on r-HGH replacement therapy</title>
            <link>http://www.medworm.com/index.php?rid=3016301&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900276X%2Fabstract%3Frss%3Dyes</link>
            <description>Patients with growth hormone (GH) deficiency (GHD) have decreased life expectancy and increased risk of cardiovascular events . An impaired fibrinolysis is a major determinant of cardiovascular risk . PAI-1, the main physiologic inhibitor of t-PA, regulates the fibrinolytic system. Raised plasma levels of PAI-1 have been documented in ischemic heart disease and in subjects who subsequently develop myocardial infarction . (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016301</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:52 +0100</pubDate>
            <guid isPermaLink="false">3016301</guid>        </item>
        <item>
            <title>Application of the Japanese Association for Acute Medicine disseminated intravascular coagulation diagnostic criteria for patients at an early phase of trauma</title>
            <link>http://www.medworm.com/index.php?rid=3016300&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003272%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The results show that the JAAM scoring system has acceptable validity for the DIC diagnosis at an early phase of trauma, and also that the scoring system can diagnose DIC with a higher sensitivity than the criteria of the ISTH overt DIC. Bleeding as well as MODS may affect the prognosis of the patients associated with DIC. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016300</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:52 +0100</pubDate>
            <guid isPermaLink="false">3016300</guid>        </item>
        <item>
            <title>Performance of two relatively new quantitative D-dimer assays (Innovance D-dimer and AxSYM D-dimer) for the exclusion of deep vein thrombosis</title>
            <link>http://www.medworm.com/index.php?rid=3016299&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003284%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: D-dimer assays are now widely used as the first-line test in the diagnostic algorithm of suspected deep vein thrombosis (DVT). The aim of this study was to evaluate the performance of two relatively new quantitative D-Dimer assays (Innovance™ and AxSYM®) by comparison with a clinical gold standard.Patients and methods: 311 samples from outpatients with clinical suspicion of DVT, included in a prospective management study, was analysed (prevalence of DVT 23%). The diagnostic workup included estimation of pre-test probability, D-dimer determination, objective imaging as well as 3 month clinical follow up of negative patients.Results: No significant differences were seen in sensitivity and negative predictive values between Innovance, AxSYM and the reference assays...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016299</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:52 +0100</pubDate>
            <guid isPermaLink="false">3016299</guid>        </item>
        <item>
            <title>The combination of recombinant factor VIIa and fibrinogen correct clotting ex vivo in patient samples obtained following cardiopulmonary bypass surgery</title>
            <link>http://www.medworm.com/index.php?rid=3016298&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003442%2Fabstract%3Frss%3Dyes</link>
            <description>In conclusion, the correction of whole blood clotting abnormalities that occurs with rFVIIa and/or fibrinogen suggests that future clinical trials on treatment of bleeding during CPB surgery should study the haemostatic effect of fibrinogen or possibly the combination of rFVIIa and fibrinogen. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016298</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:51 +0100</pubDate>
            <guid isPermaLink="false">3016298</guid>        </item>
        <item>
            <title>Modification of human blood platelet proteins induced by homocysteine and its thiolactone in vitro</title>
            <link>http://www.medworm.com/index.php?rid=3016297&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003107%2Fabstract%3Frss%3Dyes</link>
            <description>L-homocysteine (Hcys), a sulphur-containing amino acid, is an intermediate formed during the catabolism of the essential dietary amino acid methionine. Approximately 80% of plasma homocysteine is protein bound (as N-homocysteinylated (N-Hcys-protein) or S-homocysteinylated (S-Hcys-protein), that were described as N-Hcys-hemoglobin, N-(Hcys-S-S-Cys)-albumin, S-Hcys-albumin, and cysteinylhomocysteine (Cys-Hcys)), and only a small amount exists as a free reduced homocysteine (about 100 nM) . The majority of the unbound portion of Hcys is oxidized to form dimers (homocystine) or combined with cysteine to form mixed disulphides. Increased concentration of Hcys in the blood is called hyperhomocysteinemia, and in urine after oxidation of Hcys is referred to homocystinuria. The most reactive form...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016297</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:51 +0100</pubDate>
            <guid isPermaLink="false">3016297</guid>        </item>
        <item>
            <title>The role of platelets CD40 ligand (CD154) in acute coronary syndromes</title>
            <link>http://www.medworm.com/index.php?rid=3016296&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003119%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: CD154 may be used as a marker of thrombo-embolic events. Nitric oxide may have an anti-atherogenic effect. There is an association between platelet activation and severity of coronary artery disease among patients with ACS. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016296</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:51 +0100</pubDate>
            <guid isPermaLink="false">3016296</guid>        </item>
        <item>
            <title>Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-st-segment elevation acute coronary syndrome</title>
            <link>http://www.medworm.com/index.php?rid=3016295&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900190X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Platelet reactivity before PCI appears to be better predictor of myocardial damage than does response to clopidogrel. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016295</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:51 +0100</pubDate>
            <guid isPermaLink="false">3016295</guid>        </item>
        <item>
            <title>Short term effect of recombinant tissue plasminogen activator in patients with hemodynamically stable acute pulmonary embolism: Results of a meta-analysis involving 464 patients</title>
            <link>http://www.medworm.com/index.php?rid=3016294&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002242%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: Neither mortality due to pulmonary embolism nor objective pulmonary embolism recurrence are decreased by rt-PA compared with heparin in patients with hemodynamically stable pulmonary embolism. No benefit is suggested in studies including patients with right ventricular dysfunction alone. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016294</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:51 +0100</pubDate>
            <guid isPermaLink="false">3016294</guid>        </item>
        <item>
            <title>Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: A prospective, randomised study comparing two doses of parnaparin (BAFLUX STUDY)</title>
            <link>http://www.medworm.com/index.php?rid=3016293&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900214X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The dose of 4250 IU/day seems adequate to achieve prophylactic anti-Xa levels in morbid obese patients undergoing bariatric surgery. Conversely, most of the patients receiving 6.400 IU/day show anti-Xa levels higher than the recommended prophylactic values. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016293</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:51 +0100</pubDate>
            <guid isPermaLink="false">3016293</guid>        </item>
        <item>
            <title>Prospective analysis of risk factors and distribution of venous thromboembolism in the population-based Malmö Thrombophilia Study (MATS)</title>
            <link>http://www.medworm.com/index.php?rid=3016292&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002151%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: Hormone therapy, immobilisation, previous surgery and concomitant malignancy were the most common acquired risk factors among VTE patients in this population-based study. The VTE-incidence was lower than in earlier epidemiological studies. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016292</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:50 +0100</pubDate>
            <guid isPermaLink="false">3016292</guid>        </item>
        <item>
            <title>Innate immunity, coagulation and placenta-related adverse pregnancy outcomes</title>
            <link>http://www.medworm.com/index.php?rid=3016291&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003338%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Maternal immunity undergoes subtle adjustment in order to tolerate the semi-allogeneic embryo and maintain the host defense against potential pathogens. Concomitantly, coagulation systems change from an anti-coagulant state to a pro-coagulant state to meet the hemostatic challenge of placentation and delivery. Innate immunity and blood coagulation systems are the first line of defense to protect a host against exogenous challenges, including alloantigens and mechanical insults, and preserve the integrity of an organism. The interactions between coagulation and immune systems have been extensively studied. Immune cells play a pivotal role in the initiation of the coagulation cascade, whereas coagulation proteases display substantial immuno-modulatory effects. Upon exogenous challe...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016291</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:50 +0100</pubDate>
            <guid isPermaLink="false">3016291</guid>        </item>
        <item>
            <title>Heparin and maternal fetal interface: Why should it work to prevent pregnancy complications?</title>
            <link>http://www.medworm.com/index.php?rid=3016290&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003387%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Anticoagulant therapy has been used extensively for the prevention of recurrent pregnancy losses, and other placenta mediated complications, including prevention of preeclampsia and fetal growth restriction. While heparin anticoagulation is a standard treatment for antiphospholipid antibody syndrome, it is increasingly being used in the prevention of placenta mediated complications. In this article, we explore the role of heparin at maternal-fetal interface, the molecular mechanism of action for heparin, and ongoing basic and translational work being done to elucidate heparin's principal mechanisms of action. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016290</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:50 +0100</pubDate>
            <guid isPermaLink="false">3016290</guid>        </item>
        <item>
            <title>Comparing DIC scores: Not an easy task indeed</title>
            <link>http://www.medworm.com/index.php?rid=3016289&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809005015%2Fabstract%3Frss%3Dyes</link>
            <description>Several score systems for the diagnosis of disseminated intravascular coagulation (DIC) have been developed. The first score system was developed by a Japanese research group in collaboration with the Japanese Ministry of Health and Welfare (JWHW) . The International Society of Thrombosis and Hemostasis (ISTH) , and the Japanese Association for Acute Medicine (JAAM) have issued DIC score systems based on the JMHW DIC score. The DIC scores consist of the combination of clinical features (underlying disease, disease severity, DIC-related symptoms such as organ dysfunction or bleeding) with laboratory markers. The laboratory markers generally include prothrombin time (PT), platelet count, and a marker for intravascular fibrin formation. Fibrinogen, antithrombin, or protein C may be added in s...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016289</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:50 +0100</pubDate>
            <guid isPermaLink="false">3016289</guid>        </item>
        <item>
            <title>Evidence guided antiplatelet treatment: Time to move from bench to bedside</title>
            <link>http://www.medworm.com/index.php?rid=3016288&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002163%2Fabstract%3Frss%3Dyes</link>
            <description>The proaggregatory and antiaggregatory factors of the haemostatic system are finely balanced, opposing mechanisms . Before the epidemiological transition and the advent of cardiovascular disease , haemostasis was a merely protective phenomenon and there was no necessity for medical manipulation of haemostatic pathways. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016288</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:50 +0100</pubDate>
            <guid isPermaLink="false">3016288</guid>        </item>
        <item>
            <title>Thrombolysis for hemodynamically stable patients with pulmonary embolism: Still searching for the intermediate-risk group</title>
            <link>http://www.medworm.com/index.php?rid=3016287&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003156%2Fabstract%3Frss%3Dyes</link>
            <description>Morbidity and mortality associated with acute pulmonary embolism (PE) remain high despite recent advances in diagnosis and treatment. The annual incidence of the disease ranges between 23 and 69 cases per 100,000 population , and at an average case-fatality rate of approximately 11% , acute PE has been estimated to contribute to as many as 100,000 potentially preventable deaths each year in the United States alone . Importantly, acute PE covers a wide spectrum of clinical severity with mortality rates ranging between less than 1% and well over 50% in different studies . There is, at present, consensus that the principal pathophysiological factor which determines disease severity and prognosis in the acute phase of PE is the presence or absence of right ventricular (RV) dysfunction at prese...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016287</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:50 +0100</pubDate>
            <guid isPermaLink="false">3016287</guid>        </item>
        <item>
            <title>Editorial Board</title>
            <link>http://www.medworm.com/index.php?rid=3016286&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004824%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016286</comments>
            <pubDate>Sun, 22 Nov 2009 14:21:50 +0100</pubDate>
            <guid isPermaLink="false">3016286</guid>        </item>
        <item>
            <title>Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)1</title>
            <link>http://www.medworm.com/index.php?rid=2906476&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003430%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: We describe the results of a systematic literature review and an explicit approach to consensus techniques which resulted in recommendations for the key therapeutic issues in cancer patients with VTE. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906476</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:11 +0100</pubDate>
            <guid isPermaLink="false">2906476</guid>        </item>
        <item>
            <title>Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)</title>
            <link>http://www.medworm.com/index.php?rid=2906475&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003223%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Neurological disorders are often associated with immobilization, thus placing patients at increased risk for venous thromboembolism (VTE). This risk is very high in patients with acute ischemic stroke and spinal cord injuries, and it remains poorly defined in patients with peripheral nervous disorders or degenerative disorders of the central nervous system. The benefit of prophylactic strategies remains often unclear. The Italian Society for Studies on Haemostasis and Thrombosis promoted the development of evidence- and consensus-based guidelines to help physicians involved in the management of neurological patients. After a comprehensive and systematic review of the literature, a panel of experts formulated recommendations for the prevention of VTE in adolescent or adult patient...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906475</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:11 +0100</pubDate>
            <guid isPermaLink="false">2906475</guid>        </item>
        <item>
            <title>Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)</title>
            <link>http://www.medworm.com/index.php?rid=2906474&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003211%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: The term thrombophilia describes an increased tendency to develop thrombosis and many laboratory markers with different strengths of association with thrombosis have been identified. The main causes of maternal mortality and morbidity in developed countries is venous thromboembolism (VTE) and obstetric complications. During pregnancy and puerperium the risk for VTE increases due to hemostatic imbalance towards a prothrombotic state, and it is further increased in women carriers of thrombophilia; recent studies have also demonstrated an association between thrombophilia and obstetric complications. These complications are, therefore, considered potentially preventable with the prophylactic administration of anticoagulant drugs, although their efficacy is not proven by data from ra...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906474</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:11 +0100</pubDate>
            <guid isPermaLink="false">2906474</guid>        </item>
        <item>
            <title>Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)</title>
            <link>http://www.medworm.com/index.php?rid=2906473&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003041%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: The optimal management of bleeding or its prophylaxis in patients with disorders of platelet count or function is controversial. The bleeding diathesis of these patients is usually mild to moderate: therefore, transfusion of platelet concentrates may be inappropriate, as potential adverse effects might outweigh its benefit. The availability of several anti-hemorrhagic drugs further compounds this problem, mainly because the efficacy/suitability of the various treatment options in different clinical manifestations is not well defined. In these guidelines, promoted by the Italian Society for Studies on Haemostasis and Thrombosis (Società Italiana per lo Studio dell'Emostasi e della Trombosi [SISET]), we aim at offering the best available evidence to help the physicians involved in...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906473</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:11 +0100</pubDate>
            <guid isPermaLink="false">2906473</guid>        </item>
        <item>
            <title>Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)</title>
            <link>http://www.medworm.com/index.php?rid=2906472&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003429%2Fabstract%3Frss%3Dyes</link>
            <description>The objective of the present guidelines is to provide recommendations for the pre-operative and pre-procedural assessment of the bleeding risk with the aim of reducing the incidence of preventable bleeding complications and limiting laboratory tests to the those necessary.The predictive value of haemostatic tests for bleeding complications after surgery or invasive procedures has been evaluated in prospective or retrospective cohort studies only. All retrieved studies were of low methodological quality with a high potential for bias because none conducted a blinded outcome assessment. In addition, different criteria for the severity of bleeding events and different reference values of the laboratory tests were adopted. The low methodological quality limits the validity of the results of th...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906472</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:10 +0100</pubDate>
            <guid isPermaLink="false">2906472</guid>        </item>
        <item>
            <title>Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)</title>
            <link>http://www.medworm.com/index.php?rid=2906471&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002497%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: A current goal of the Italian Society for Thrombosis and Haemostasis (SISET) is the production of guidelines for clinical conditions related to haemostasis and thrombosis. In 2006, the Executive Committee of SISET adopted a new program for the production of methodologically and scientifically sound guidelines aimed at both addressing clinical practice and stimulating new research. The first major step for this program was to train methodologists to manage working groups that compose the guidelines, and to create a reference document that describes the development of the program. The aim of the present paper is to report a short version of this methodological document, for those who wish to follow SISET guidelines. We start by giving a brief outline of the SISET mission, then pres...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906471</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:10 +0100</pubDate>
            <guid isPermaLink="false">2906471</guid>        </item>
        <item>
            <title>A novel cholesterol absorption inhibitor, ezetimibe, decreases adipose-derived and vascular PAI-1 expression in vivo</title>
            <link>http://www.medworm.com/index.php?rid=2906470&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002266%2Fabstract%3Frss%3Dyes</link>
            <description>Hypercholesterolemia is an independent risk factor for the development of atherosclerosis and cardiovascular/thrombotic diseases. The increased incidence of cardiovascular disease may be associated with elevated levels of coagulation factors and plasminogen activator inhibitor-1 (PAI-1) in plasma, which is the primary inhibitor of plasminogen activation in vivo . PAI-1 levels in plasma are elevated in hyperlipidemic and/or obese patients , and adipose tissue is one of primary sources of PAI-1 production in this condition . These observations suggest that PAI-1 expression could be substantially influenced by lipid metabolism. For example, PAI-1 expression in cultured adipocytes is strongly upregulated by glucocorticoids, insulin, tumor necrosis factor-α, and LDL, some of which have been fo...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906470</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:10 +0100</pubDate>
            <guid isPermaLink="false">2906470</guid>        </item>
        <item>
            <title>A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia: An update</title>
            <link>http://www.medworm.com/index.php?rid=2906469&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002977%2Fabstract%3Frss%3Dyes</link>
            <description>We recently published a clinical-laboratory approach for the diagnosis of heparin-induced thrombocytopenia (HIT) . Our study confirmed that the combination of the ID-heparin (H)/platelet factor 4 (PF4) PaGIA® (Diamed, Cressier sur Morat, Switzerland) with the clinical 4T's score is a reliable screening strategy to rule out or support rapidly the diagnosis of HIT. Yet, the flow cytometric measurement of the CD62p-expression (flowCD62p) remains necessary to confirm the presence of functional relevant antibodies in patients with clinical features of HIT, especially when the clinical situation is not straightforward (intermediate risk group). This combined diagnostic work-up is considered to have the advantage to contribute in a rapid and reliable way to the definite diagnosis of HIT. (Source...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906469</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:10 +0100</pubDate>
            <guid isPermaLink="false">2906469</guid>        </item>
        <item>
            <title>What is blood borne tissue factor?</title>
            <link>http://www.medworm.com/index.php?rid=2906468&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003144%2Fabstract%3Frss%3Dyes</link>
            <description>In a recent letter to the Editors-in-Chief of Thrombosis Research we reported on blood borne TF . Microparticles and monocytes were isolated from non-stimulated and LPS- and LPS+PMA-stimulated whole blood and their TF antigen and activity quantified using an immunoblot technique and a specific two stage assay, respectively. This approach indicated that circulating microparticles had quite a high content of TF antigen, even though their TF activity turned out extremely low. Thus their specific TF activity was found to be very low compared to that of resting as well as stimulated monocytes of whole blood. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906468</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:10 +0100</pubDate>
            <guid isPermaLink="false">2906468</guid>        </item>
        <item>
            <title>Biochemical and Hemostatic Mechanism of A Novel Thrombin-Like Enzyme</title>
            <link>http://www.medworm.com/index.php?rid=2906467&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002758%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Thrombin-like enzyme (TLE) plays a significant role in vessel injury hemostasis. A novel snake venom TLE (Agacutin) was purified from Agkistrodon Acutus snake venom. Structural analysis indicated that Agacutin is a heterodimer that has a MW of 29,402 Da, a pI value of 5.39, and optimum activity at 35 °C and pH 7.5. The N-terminal 15 amino acid sequences of Agacutin are DSSGWSSYEGHEYYV (small subunit) and DCSSGWSSYEEHQYY (large subunit). In vitro studies indicated that the coagulation activity of Agacutin was activated by Ca+2 or inhibited by phenylmethanesulfonyl fluoride, but not influenced by heparin or hirudin. The arginine esterase activity and fibrinogen hydrolysis result showed that Agacutin only cleaves α-subunit and releases fibrinopeptide A. In vivo studies indicated...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906467</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:10 +0100</pubDate>
            <guid isPermaLink="false">2906467</guid>        </item>
        <item>
            <title>Long term administration of LMWH - pharmacodynamic parameters under therapeutic or prophylactic regimen of enoxaparin or tinzaparin in neurological rehabilitation patients</title>
            <link>http://www.medworm.com/index.php?rid=2906466&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003053%2Fabstract%3Frss%3Dyes</link>
            <description>In conclusion, although marked differences between tinzaparin and enoxaparin based on anti-FXa-activity were seen, markers of in vivo biological activity such as TFPI and D-dimer were not different. Furthermore, BID tinzaparin is a feasible option for therapeutic anticoagulation in patients with high bleeding risk. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906466</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:10 +0100</pubDate>
            <guid isPermaLink="false">2906466</guid>        </item>
        <item>
            <title>Gene polymorphisms and risk of adult early-onset ischemic stroke: A meta-analysis</title>
            <link>http://www.medworm.com/index.php?rid=2906465&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900317X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Genetic abnormalities specific to homocysteine and lipid metabolism increase the risk for ischemic stroke at an early age. These data may offer important implications for future genetic association studies for stroke. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906465</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:10 +0100</pubDate>
            <guid isPermaLink="false">2906465</guid>        </item>
        <item>
            <title>Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome</title>
            <link>http://www.medworm.com/index.php?rid=2906464&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900320X%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: In patients with coronary disease at risk of acute coronary events it is unclear which biological factors could predict the type of acute coronary syndrome clinical presentation. The aim of the study was to investigate the role of genetic polymorphisms in key proteins in fibrinolysis in the type of acute coronary syndrome.Materials and methods: 248 patients with acute coronary syndrome (unstable angina or myocardial infarction) (77% male, mean age 60.75 SD 13.30years) were prospectively recruited. PAI-1 (type-1 plasminogen activator inhibitor) 4G/5G and TAFI (thrombin-activatable fibrinolysis inhibitor) Ala147Thr, C+1542G, and Thr325Ile polymorphisms were determined by PCR.Results: 147 (59.3%) patients presented with ST-segment elevation acute coronary syndrome (all...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906464</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:09 +0100</pubDate>
            <guid isPermaLink="false">2906464</guid>        </item>
        <item>
            <title>Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality</title>
            <link>http://www.medworm.com/index.php?rid=2906463&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003259%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: DIC with a fibrinolytic phenotype modified through fibrinogenolysis at an early phase of trauma contributes to poor prognosis due to massive bleeding. Tissue hypoperfusion may be involved in the pathogenesis of this type of DIC. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906463</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:09 +0100</pubDate>
            <guid isPermaLink="false">2906463</guid>        </item>
        <item>
            <title>Factor VIII contributes to platelet-fibrin thrombus formation via thrombin generation under low shear conditions</title>
            <link>http://www.medworm.com/index.php?rid=2906462&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003260%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: These results suggest that FVIII contributes to platelet aggregation and fibrin formation via thrombin generation under low shear conditions. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906462</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:09 +0100</pubDate>
            <guid isPermaLink="false">2906462</guid>        </item>
        <item>
            <title>Release of necrosis markers and cardiovascular magnetic resonance-derived microvascular perfusion in reperfused ST-elevation myocardial infarction</title>
            <link>http://www.medworm.com/index.php?rid=2906461&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002539%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: In ST-elevation myocardial infarction, a larger release of cardiac necrosis markers soon after reperfusion therapy relates to abnormal perfusion. Troponin appears as the most reliable necrosis marker for an early detection of cardiovascular magnetic resonance-derived abnormal microvascular reperfusion. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906461</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:09 +0100</pubDate>
            <guid isPermaLink="false">2906461</guid>        </item>
        <item>
            <title>Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy</title>
            <link>http://www.medworm.com/index.php?rid=2906460&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002989%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: By in vitro testing, cigarette smoking is associated with enhanced clopidogrel- but not aspirin-mediated platelet inhibition. The clinical implications have to be evaluated in large prospective trials. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906460</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:09 +0100</pubDate>
            <guid isPermaLink="false">2906460</guid>        </item>
        <item>
            <title>Increase in proinflammatory cytokines in peripheral blood without haemostatic changes after LPS inhalation</title>
            <link>http://www.medworm.com/index.php?rid=2906459&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002990%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: This study confirms that despite systemic release of proinflammatory cytokines, LPS inhalation does not induce systemic haemostatic response to LPS challenge. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906459</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:09 +0100</pubDate>
            <guid isPermaLink="false">2906459</guid>        </item>
        <item>
            <title>Effect of tissue inhibitor of matrix metalloproteinases-1 on in vitro and in vivo adipocyte differentiation</title>
            <link>http://www.medworm.com/index.php?rid=2906458&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003065%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) play a role in development of obesity by contributing to adipogenesis, angiogenesis and extracellular matrix degradation. We have evaluated a potential functional role of TIMP-1, which inhibits most MMPs, in early stages of in vitro and in vivo adipogenesis. Overexpression of human TIMP-1 (hTIMP-1) in 3T3-F442A preadipocytes resulted in a somewhat slower differentiation into mature adipocytes, without affecting the total extent of differentiation. Local overexpression by injection of 3T3-F442A preadipocytes expressing hTIMP-1 in the back of NUDE mice kept on high fat diet (HFD) for 4 weeks, had no effect on de novo formed fat pad mass. The fat pads formed from the hTIMP-1 expressing cells did show a significant...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906458</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:08 +0100</pubDate>
            <guid isPermaLink="false">2906458</guid>        </item>
        <item>
            <title>Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery</title>
            <link>http://www.medworm.com/index.php?rid=2906457&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003089%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: A substantial number of patients with coronary artery disease undergo cardiac surgery within five days of discontinuing anti-platelet treatment with aspirin and clopidogrel. The aims of this study were to describe the degree of platelet inhibition in patients with dual anti-platelet treatment scheduled for coronary artery bypass graft (CABG) surgery and to investigate whether the measured platelet inhibition correlated to intra- and postoperative risk for bleeding and transfusion requirements.Material and Methods: Sixty patients were included. Platelet inhibition was analysed with flow cytometry including phosphorylation status of the vasodilator-stimulated phosphoprotein (VASP-assay) and two bed-side analyzers, VerifyNow-System and PlateletMapping, a modified throm...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906457</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:08 +0100</pubDate>
            <guid isPermaLink="false">2906457</guid>        </item>
        <item>
            <title>Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis</title>
            <link>http://www.medworm.com/index.php?rid=2906456&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003090%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Ticagrelor (AZD6140), the first reversibly binding oral P2Y12 receptor antagonist, blocks adenosine diphosphate (ADP)-induced platelet aggregation via a mode of action distinct from that of thienopyridine antiplatelet agents. The latter must be metabolically activated and binds irreversibly to P2Y12 for the life of the platelet, precluding restoration of hemostatic function without the generation of new platelets. In in vitro studies comparing binding characteristics of ticagrelor and compound 105, a chemical compound indistinguishable from the active metabolite of prasugrel, ticagrelor exhibited 1) an approximately 100-fold higher affinity for P2Y12 and rapid achievement of equilibrium (vs no equilibrium reached with compound 105) as assessed by radioligand displacement in a rec...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906456</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:08 +0100</pubDate>
            <guid isPermaLink="false">2906456</guid>        </item>
        <item>
            <title>The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina</title>
            <link>http://www.medworm.com/index.php?rid=2906455&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001698%2Fabstract%3Frss%3Dyes</link>
            <description>The objective of this study was to investigate the time profiles of plasma matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinases (TIMP-1 and -2), and pregnancy associated plasma protein A (PAPP-A) in patients with acute myocardial infarction (AMI), compared to patients with stable angina pectoris (AP), all treated with percutaneous coronary intervention (PCI) with stent.Methods: Twenty patients with ST-elevation AMI and 10 patients with AP were included. Serum levels of the selected markers were measured before (only in the AP group) PCI, and 3 and 12 hours, 1,3,5,7 and 14 days after PCI in all patients.Results: The levels of MMP-9 and MMP-9/TIMP-1 ratio, being higher in the AMI group compared to the AP group at 3 hours, were significantly reduced 1 day after PCI (...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906455</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:08 +0100</pubDate>
            <guid isPermaLink="false">2906455</guid>        </item>
        <item>
            <title>Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia</title>
            <link>http://www.medworm.com/index.php?rid=2906454&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001819%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: This study supports the recommendations concerning the management of HIT patients, namely discontinuation of all heparin administration once the diagnosis is suspected and prompt initiation of an alternative anticoagulant drug with a strict adherence to doses specifically recommended for these patients. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906454</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:08 +0100</pubDate>
            <guid isPermaLink="false">2906454</guid>        </item>
        <item>
            <title>Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel</title>
            <link>http://www.medworm.com/index.php?rid=2906453&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001820%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: When assessing platelet aggregation following clopidogrel, measurement of late aggregation after addition of ADP 20 µM should be preferred. Large clinical trials should be conducted to assess which parameter between residual aggregation or inhibition of platelet aggregation by clopidogrel best predicts clinical efficacy of the drug. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906453</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:08 +0100</pubDate>
            <guid isPermaLink="false">2906453</guid>        </item>
        <item>
            <title>Decreased ADAMTS13 Levels in Patients after Living Donor Liver Transplantation</title>
            <link>http://www.medworm.com/index.php?rid=2906452&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001923%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: A significant reduction of ADAMTS13 and an increase of VWF were observed in the patients with TMALS. The ADAMTS13 activity in patients after LDLT was significantly reduced from day 1 to day 21, and it was significantly low in those with TMALS at day 14 and 28. The VWF levels in patients with LDLT were significantly high, and the VWF/ADAMTS13 ratio was significantly increased in patients at 7, 14 and 28 days after LDLT, especially in patients with TMALS at day 14 and 28 after LDLT. High molecular weight multimers of VWF were observed to have increased in patients with LDLT, and the high molecular weight multimers of VWF were further increased in those with mild TMALS but they decreased in those with severe TMA. These findings suggest that ULM- VWF and ADAMTS13 might be associa...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906452</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:07 +0100</pubDate>
            <guid isPermaLink="false">2906452</guid>        </item>
        <item>
            <title>Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention</title>
            <link>http://www.medworm.com/index.php?rid=2906451&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001935%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Background and aims: Patency of infarct-related artery (IRA) before mechanical reperfusion with primary percutaneous coronary intervention (PPCI) has been associated with better prognosis in patients with ST-Elevation myocardial infarction (STEMI). Mean platelet volume (MPV) increases in STEMI patients and may be associated with increased thrombotic potential. In STEMI patients scheduled for PPCI we sought to assess whether mean platelet volume (MPV), as measured at admission, correlates with “spontaneous” reperfusion of the IRA and short-term clinical outcome.Methods: Blood samples were obtained on hospital admission in 617 consecutive patients (82% men; age 64±12 years) with STEMI, before PPCI. 372 (61%) patients were treated with the GP IIb/IIIa blocker abciximab. The ma...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906451</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:05 +0100</pubDate>
            <guid isPermaLink="false">2906451</guid>        </item>
        <item>
            <title>Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO)</title>
            <link>http://www.medworm.com/index.php?rid=2906450&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001947%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: ROC-patients appear to have the highest risk for developing VTE when ascites exists and during the first 2 months following chemotherapy initiation. In contrast to primary ovarian cancer, VTE could not be identified to affect overall survival in relapsed malignant ovarian disease. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906450</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:05 +0100</pubDate>
            <guid isPermaLink="false">2906450</guid>        </item>
        <item>
            <title>Prothrombin fragment 1+2 is associated with intima media thickness of the carotid artery in patients with myocardial infarction</title>
            <link>http://www.medworm.com/index.php?rid=2906449&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001959%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Background and aim: Previous studies have shown that a decreased fibrinolytic activity or a hyperactivated coagulation system increase the risk of myocardial infarction. The aim of this study was to investigate the relationship between the presence of atherosclerotic lesions and coagulation and fibrinolysis factors and high sensitivity CRP (hs-CRP) in patients with myocardial infarction.Methods: In a cross-sectional study, 123 patients, aged 31-80 years, with a history of previous myocardial infarction were examined with B-mode ultrasound of the common carotid artery. Blood samples were collected for measurements of fibrinogen, plasminogen activator inhibitor-1 activity (PAI-1), von Willebrand factor (vWF), prothrombin fragment 1+2 and hs-CRP.Results: Prothrombin fragment 1+2 an...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906449</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:05 +0100</pubDate>
            <guid isPermaLink="false">2906449</guid>        </item>
        <item>
            <title>Mechanisms of antiphospholipid antibody-associated pregnancy complications</title>
            <link>http://www.medworm.com/index.php?rid=2906448&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003326%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Women with antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL) are at high risk for recurrent spontaneous miscarriage and late pregnancy complications, such as preeclampsia and preterm labor. Recent clinical and experimental observations suggest that the pathophysiology of pregnancy failure in patients with APS may involve inflammation at the maternal-fetal interface and disruption of normal trophoblast function and survival, rather than a pro-thrombotic event. While treatment with heparin and aspirin from early pregnancy has been shown to significantly increase the live birth rate in recurrent miscarriage patients with APS, the incidence of severe late pregnancy complications still remains high. This review will discuss what is currently known about the mechani...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906448</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:05 +0100</pubDate>
            <guid isPermaLink="false">2906448</guid>        </item>
        <item>
            <title>Involvement of human decidual cell-expressed tissue factor in uterine hemostasis and abruption</title>
            <link>http://www.medworm.com/index.php?rid=2906447&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003314%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Vascular injury increases access and binding of plasma-derived factor VII to perivascular cell membrane-bound tissue factor (TF). The resulting TF/VIIa complex promotes hemostasis by cleaving pro-thrombin to thrombin leading to the fibrin clot. In human pregnancy, decidual cell-expressed TF prevents decidual hemorrhage (abruption). During placentation, trophoblasts remodel decidual spiral arteries into high conductance vessels. Shallow trophoblast invasion impedes decidual vascular conversion, producing an inadequate uteroplacental blood flow that elicits abruption-related placental ischemia. Thrombin induces several biological effects via cell surface protease activated receptors. In first trimester human DCs thrombin increases synthesis of sFlt-1, which elicits placental ischem...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906447</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:05 +0100</pubDate>
            <guid isPermaLink="false">2906447</guid>        </item>
        <item>
            <title>Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)</title>
            <link>http://www.medworm.com/index.php?rid=2906446&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809004149%2Fabstract%3Frss%3Dyes</link>
            <description>In the current issue of Thrombosis Research, we publish the first series of six guidelines produced by the Italian Society for Haemostasis and Thrombosis (Società Italiana per lo Studio dell'Emostasi e della Trombosi — SISET) . These guidelines are the first articles to be published on-line only as part of a new publication strategy of Thrombosis Research . (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906446</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:04 +0100</pubDate>
            <guid isPermaLink="false">2906446</guid>        </item>
        <item>
            <title>Editorial Board</title>
            <link>http://www.medworm.com/index.php?rid=2906445&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900440X%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906445</comments>
            <pubDate>Tue, 20 Oct 2009 13:24:04 +0100</pubDate>
            <guid isPermaLink="false">2906445</guid>        </item>
        <item>
            <title>Inherited thrombophilia in patients with thrombotic thrombocytopenic purpura</title>
            <link>http://www.medworm.com/index.php?rid=2754455&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002011%2Fabstract%3Frss%3Dyes</link>
            <description>Thrombotic thrombocytopenic purpura (TTP) is a rare, but life-threatening disorder, characterized by thrombi in the microvasculature, resulting in vascular occlusions that lead to tissue ischemia and end-organ injury . The presenting triad of microangiopathic hemolytic anemia, thrombocytopenia and neurologic symptoms is found in the majority of patients, while the pentad including fever and renal involvement is present in 40% of the patients. A severe deficiency of ADAMTS13, caused by a genetic mutation or inhibitory autoantibodies, is considered the underlying pathophysiological mechanism . Although the incidence of prothrombotic polymorphisms in TTP patients has been explored , data reported so far are contradictory. Raife et al. suggested that factor V Leiden could be a pathogenetic ris...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754455</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754455</guid>        </item>
        <item>
            <title>A rare case of MYH9 disorders presenting with macrothrombocytopenia and deafness caused by MYH9-R702C mutation</title>
            <link>http://www.medworm.com/index.php?rid=2754454&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809000966%2Fabstract%3Frss%3Dyes</link>
            <description>Giant platelets often appear in acquired thrombocytopenia, such as idiopathic thrombocytopenic purpura (ITP) and myelodysplastic syndrome1. Congenital macrothrombocytopenia is rare, and consists of a variety of diseases , including 4 autosomal dominant disorders, May-Hegglin anomaly, and Sebastian, Fechtner, and Epstein syndromes, which have neutrophil inclusion bodies (Döhle-like bodies), or Alport-like symptoms (nephritis, deafness, or cataract) . These diseases have been differentiated by expression pattern and morphology of neutrophil inclusion bodies, or the clinical features of Alport-like manifestations . Mutations of the non-muscle myosin heavy chain 9 (MYH9) gene which encodes non-muscle myosin heavy chain IIA (NMMHC-IIA), however, were identified in all 4 disorders . From this v...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754454</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754454</guid>        </item>
        <item>
            <title>The effect of high circulating estradiol levels on thrombin generation during in vitro fertilization</title>
            <link>http://www.medworm.com/index.php?rid=2754453&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001145%2Fabstract%3Frss%3Dyes</link>
            <description>In vitro fertilization (IVF) is a well-documented risk factor for thromboembolic complications . Suspected complications have included jugular venous thrombosis , carotid thrombosis , and fatal cerebral infarction . Possible plasma factor compositional reasons for the link between IVF and thrombotic events include activated protein C resistance , decreased protein S and antithrombin (AT) , and increased fibrinogen and factor (F) VIII . These factors could potentiate increased thrombin generation. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754453</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754453</guid>        </item>
        <item>
            <title>Increased phosphatidylserine exposure on platelets from hospitalized patients with acute medical illnesses</title>
            <link>http://www.medworm.com/index.php?rid=2754452&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001194%2Fabstract%3Frss%3Dyes</link>
            <description>Activated platelets expose pro-coagulant phospholipids which catalyze the generation of thrombin by several-folds . Phosphatidylserine (PS) is one of the platelet membrane phospholipids which contributes most to the assembly of tenase and prothrombinase complexes PS is expressed on the inner leaflet of the membrane of non-stimulated platelets while it becomes actively transported on the outer layer upon cell activation . The PS-dependent platelet pro-coagulant activity is partly antagonised by annexin-V which binds to and forms a protective shield over exposed phospholipids such as PS Changes in lipid distributions with the outward expression of PS have been described in several pro-thrombotic conditions including the anti-phospholipid syndrome or in chronic renal failure . No data are cur...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754452</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754452</guid>        </item>
        <item>
            <title>The expression of 4 protease-activated receptors is associated with increased levels of TNF-α, tissue factor, and fibrin in the frontal cortex of endotoxemic rats</title>
            <link>http://www.medworm.com/index.php?rid=2754451&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001911%2Fabstract%3Frss%3Dyes</link>
            <description>Sepsis produces brain dysfunction, termed sepsis-associated encephalopathy . Pathological examinations have revealed the cerebral cortex to be the most commonly involved site . The main pathologic signs found in the brain of patients with septic shock are hemorrhage, hypercoagulability syndrome, microabscess formation, leucoencephalopathy, and ischemia . The pathogenesis of sepsis-associated encephalopathy is multifactorial, involving microvascular disorder, endothelial activation, breakdown of the blood-brain barrier (BBB), brain inflammation, neuronal degeneration, and apoptosis . (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754451</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754451</guid>        </item>
        <item>
            <title>Implementation of the ISTH classification of non-overt DIC in a thromboplastin induced rabbit model</title>
            <link>http://www.medworm.com/index.php?rid=2754450&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002461%2Fabstract%3Frss%3Dyes</link>
            <description>In this study, we use rabbit brain thromboplastin (thromboplastin) to induce DIC in a rabbit model and test the applicability of the ISTH criteria for standardized diagnosis of DIC.Cardiovascular and haematological parameters from rabbits, either saline-injected or administered 0.625, 1.25, 2.5 or 5 mg thromboplastin/kg as a single bolus, were collected at four timepoints over a 90 minute period. All groups of rabbits were scored at each time point according to the ISTH diagnostic criteria for non-overt DIC.Injection of 5 mg thromboplastin/kg was lethal. For the remaining groups, a dose dependent decrease in blood pressure, platelet count and fibrinogen level together with a dose dependent increase in prothrombin time, activated partial thromboplastin time, level of thrombin-antithrombi...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754450</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754450</guid>        </item>
        <item>
            <title>Hyperglycaemia impairs antithrombin secretion: Possible contribution to the thrombotic risk of diabetes</title>
            <link>http://www.medworm.com/index.php?rid=2754449&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002552%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Recent data support that diabetes might be a conformational disease. Certainly, hyperglycaemia causes a broad range of deleterious effects that might facilitate protein aggregation. We have evaluated the effects of hyperglycaemia on antithrombin, a conformationally sensitive serpin with a potent anticoagulant role. Moreover, these studies might also help to understand the thrombotic risk associated to diabetes. We incubated in vitro plasma and purified antithrombin and human hepatoma cells (HepG2) with methyl-glyoxal and glucose. Moreover, a mouse model of acute diabetes was generated with streptozotocin. Antigen, anti-FXa activity, heparin affinity and conformational features of antithrombin were analysed. Histological and intracellular features and distribution of antithrombin ...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754449</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754449</guid>        </item>
        <item>
            <title>Allicin and disulfiram enhance platelet integrin αIIbβ3-fibrinogen binding</title>
            <link>http://www.medworm.com/index.php?rid=2754448&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002965%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Allicin and disulfiram inhibit agonist-induced washed platelet activation probably via inhibition of platelet signaling, but enhance PT25-2 antibody-induced αIIbβ3 integrin activity most likely by preventing reformation of disulfide bridges thereby stabilizing the active conformation of the integrin. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754448</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754448</guid>        </item>
        <item>
            <title>Immobilization and the risk of venous thromboembolism. A meta-analysis on epidemiological studies</title>
            <link>http://www.medworm.com/index.php?rid=2754447&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002187%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Background: The thrombogenic burden of immobilization remains unknown especially in the medical setting. Most of epidemiological studies estimating the link between risk factors and venous thromboembolism (VTE) have not been designed to evaluate immobilization. The aim of this work was to estimate the risk of VTE in medical bedridden patients by a systematic review and a meta-analysis.Methods: A research on PUBMED and EMBASE was carried out to retrieve case-control and cohort studies showing the proportion of bedridden patients with or without VTE. Included studies were assigned in six groups according to the following criteria: 1) their design (cohort or case-control), 2) the targeted population (with or without suspicion of VTE) and 3) the medical setting (ambulatory or hospita...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754447</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754447</guid>        </item>
        <item>
            <title>Lipopolysaccharide-induced activation of coagulation in neonatal cord and adult blood monitored by thrombelastography</title>
            <link>http://www.medworm.com/index.php?rid=2754446&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002175%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: In summary, TEG proved to be a sensitive and reliable tool for the determination of LPS-induced tissue factor mediated activation of hemostasis in whole blood samples from adults and neonates. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754446</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754446</guid>        </item>
        <item>
            <title>Association of the -757T&gt;C polymorphism in the CRP gene with circulating C-reactive protein levels and carotid atherosclerosis</title>
            <link>http://www.medworm.com/index.php?rid=2754445&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002023%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The present study provides evidence that a genetic variant of CRP gene is associated with carotid atherosclerosis, independently of traditional vascular risk factors. Further large-scale genomic studies are required, which may identify the genetic vulnerable subjects to develop atherosclerosis. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754445</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754445</guid>        </item>
        <item>
            <title>Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease</title>
            <link>http://www.medworm.com/index.php?rid=2754444&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002059%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: Increased oxidative stress (SOX) is one of the most potent inductors of endothelial dysfunction in end-stage renal disease (ESRD) patients. Kynurenines are the metabolites of tryptophan (TRP) degradation in mammals. However, the role of kynurenines in the function of the endothelium is still not recognized.Materials and methods: We determined the plasma concentrations of TRP, kynurenine (KYN), 3-hydroxykynurenine (3-HKYN), quinolinic acid (QA); markers of SOX: Cu/Zn superoxide dismutase (Cu/Zn SOD), malondialdehyde (MDA); and endothelial dysfunction markers: thrombomodulin (TM) and von Willebrand factor (vWF) levels in 148 ESRD patients and healthy controls.Results: TM, vWF, KYN, 3-HKYN and QA levels were significantly elevated in ESRD patients compared to controls....</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754444</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754444</guid>        </item>
        <item>
            <title>Shear-induced global thrombosis test of native blood: Pivotal role of ADP allows monitoring of P2Y12 antagonist therapy</title>
            <link>http://www.medworm.com/index.php?rid=2754443&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002060%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Background: It is claimed that in shear-induced platelet function tests, shear-stress is the sole agonist causing platelet activation and resultant thrombosis. However, the fact that red blood cells (RBC) are essential to achieve platelet aggregation in these tests supports recent evidence that ADP makes an important contribution to shear-induced platelet reaction.Aim: To establish the role of ADP in shear-induced thrombosis, and investigate whether a shear-induced thrombosis test can assess ADP-receptor (P2Y12) antagonist medication.Methods: Blood from healthy volunteers was tested using the Global Thrombosis Test (GTT), before and after clopidogrel. To investigate the importance of contact of blood with plastic, the reactive part of the tube was primed with saline. We also inve...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754443</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754443</guid>        </item>
        <item>
            <title>Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells</title>
            <link>http://www.medworm.com/index.php?rid=2754442&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002576%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The NADPH oxidase inhibitors DPI and S 17834 as well as Nox4 silencing decreased PAI-1 synthesis in human cultured endothelial cells demonstrating the involvement of the constitutively active Nox4-containing NADPH oxidase in ROS-mediated PAI-1 transcription via p38 MAPK pathways. NADPH oxidase targeting with inhibitors such as S17834 could be an interesting strategy to decrease both oxidative stress and PAI-1 synthesis. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754442</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754442</guid>        </item>
        <item>
            <title>Dependence of platelet function on underlying liver disease in orthotopic liver transplantation</title>
            <link>http://www.medworm.com/index.php?rid=2754441&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002953%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: In the entire process of OLT, coagulation factors, maximum aggregation and rate of platelet aggregation depend on the surgical phases during transplantation and on the underlying liver disease. The data obtained in this study might contribute to a better understanding of the pathophysiology and assessment of bleeding risk in OLT. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754441</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754441</guid>        </item>
        <item>
            <title>Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia</title>
            <link>http://www.medworm.com/index.php?rid=2754440&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809000292%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The increased risk of thrombosis in thrombophilia patients is not only ascribable to an increased thrombin generation, but also high levels of proCPU and the presence of the 325Ile genotype tip the balance towards thrombotic tendency even further. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754440</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754440</guid>        </item>
        <item>
            <title>Haemostatic markers in patients with abdominal aortic aneurysm and the impact of aneurysm size</title>
            <link>http://www.medworm.com/index.php?rid=2754439&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809000954%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The present data indicate a state of activated coagulation in patients with abdominal aortic aneurysm which is dependent by aneurysm size. The activated coagulation in AAA patients could contribute to an increased cardiovascular risk in patients also with small AAA. The possible impact of secondary prevention apart from smoking cessation has to be further evaluated and is maybe as important as finding patients at risk of rupture. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754439</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754439</guid>        </item>
        <item>
            <title>Evaluation of the platelet count drop method for assessment of platelet function in comparison with “gold standard” light transmission aggregometry</title>
            <link>http://www.medworm.com/index.php?rid=2754438&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809000978%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: Hyporesponsiveness to antiplatelet agents has been linked to an increased risk of major adverse cardiovascular events. However, light transmission aggregometry (LTA), the gold standard methodology for assessing platelet function, requires expertise and is labour-intensive, which render its use in clinical settings impractical. We assessed whether platelet count drop (PCD), a technique widely available in any haematology laboratory, could replace LTA in testing for inhibition of platelet aggregation induced by antiplatelet agents.Materials and methods: One hundred and sixty-one coronary artery disease patients taking aspirin alone and 91 patients taking a combination of aspirin and clopidogrel were enrolled. Platelet aggregation was measured by LTA and PCD stimulated...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754438</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754438</guid>        </item>
        <item>
            <title>Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review</title>
            <link>http://www.medworm.com/index.php?rid=2754437&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001121%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Our systematic review suggests that V617F Jak-2 increases the risk of thrombosis in essential thrombocythaemia patients by about two fold while its role in idiopathic myelofibrosis patients is uncertain. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754437</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754437</guid>        </item>
        <item>
            <title>Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer</title>
            <link>http://www.medworm.com/index.php?rid=2754436&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001285%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: Plasminogen activator inhibitor (PAI-1) may have an independent prognostic value in breast cancer (BC). PAI-1 4G/5G polymorphism may have significance for antigen expression. Thus, we analyzed the possible associations between PAI-1 4G/5G polymorphism, plasma PAI-1 levels, and clinicopathological features of breast cancer (BC) patients.Patients and Methods: PAI-1 4G/5G polymorphism (both on germinal and tumor DNA) and plasma PAI-1 levels were investigated in 99 BC patients and 50 unrelated healthy women similar for age and menopausal status.Results: No association was found between allele frequencies and clinicopathological features of BC or plasma antigen levels. Plasma PAI-1 levels were higher in BC compared to controls (p=0.002), particularly in patients with lar...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754436</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754436</guid>        </item>
        <item>
            <title>Prothrombotic factors and the risk of acute onset non-cardioembolic stroke in young Asian Indians</title>
            <link>http://www.medworm.com/index.php?rid=2754435&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001601%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: Several prothrombotic factors – both hereditary and acquired – are known to cause stroke. Commonly investigated causes are activated protein C resistance, factor V Leiden mutation, factor VIII levels, prothrombin 20210 G-to-A mutation, coagulation inhibitors such as proteins C and S, and antiphospholipid antibodies such as β2-glycoprotein.Objective: The literature on the prevalence of hematological defects pertaining to these variables in the Asian Indian stroke population is limited to a few isolated reports. In the current study we investigate the above-mentioned variables in 120 stroke patients (non-cardioembolic acute-onset stroke) and compare their status with the hematological profile of an equal number of healthy age- and sex-matched controls.Material an...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754435</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754435</guid>        </item>
        <item>
            <title>Tissue factor and the endometrium: From physiology to pathology</title>
            <link>http://www.medworm.com/index.php?rid=2754434&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002746%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Tissue factor (TF), is a transmembrane protein whose role was first identified as that of the initiator of hemostasis via a series of complicated protein cascades. It is now known however, that TF participates in angiogenesis as well as several processes that contribute to disease progression.Over the last 20 years, our laboratory has studied the expression and function of this molecule in both the pregnant and non-pregnant human endometrium. We demonstrated that TF is particularly upregulated at the time of implantation making it a critical factor to protect against excessive bleeding during trophoblast invasion. We have subsequently demonstrated the altered expression of this factor after long term contraception as well as in endometriosis. We proposed that any changes in this ...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754434</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754434</guid>        </item>
        <item>
            <title>Role of the syncytium in placenta-mediated complications of preeclampsia</title>
            <link>http://www.medworm.com/index.php?rid=2754433&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809002540%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: The syncytiotrophoblast (SCT) is the outer layer of placenta which is in direct contact with maternal blood. As such it is uniquely positioned to alter maternal hemostasis and endothelial function. The syncytium is known to release anti-angiogenic factors including fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), as well as the anti-fibinolytic factor plasminogen activator inhibitor-1 (PAI-1). Its release of microparticles has also been suggested to play a role in regulating maternal endothelial and immune cell function. It is of note that syncytial release of the abovementioned factors increases in preeclampsia, a major cause of maternal mortality and morbidity. In preeclampsia, hypoxia and reperfusion injury in the placenta is associated with activation of the m...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754433</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754433</guid>        </item>
        <item>
            <title>Thrombosis and regulation of the trophoblast at the maternal interface</title>
            <link>http://www.medworm.com/index.php?rid=2754432&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809003375%2Fabstract%3Frss%3Dyes</link>
            <description>In this series of six reviews to be published in Thrombosis Research over the next three issues, we explore the many facets of thrombosis at the uteroplacental interface, in order to provide readers with insight into current trends in basic and translational research striving to explain placenta mediated complications. Ultimately, improved prevention and treatment paradigms, grounded in robust and cumulative scientific evidence, will ultimately emerge. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754432</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754432</guid>        </item>
        <item>
            <title>Editorial Board</title>
            <link>http://www.medworm.com/index.php?rid=2754431&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS004938480900379X%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2754431</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2754431</guid>        </item>
        <item>
            <title>Influence of antithrombin and argatroban on disseminated intravascular coagulation parameters in a patient with septic shock</title>
            <link>http://www.medworm.com/index.php?rid=2596060&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384808005069%2Fabstract%3Frss%3Dyes</link>
            <description>Sepsis is a leading cause of mortality in intensive care and is commonly associated with disseminated intravascular coagulation (DIC), characterized by massive systemic intravascular coagulation activation and inhibition of fibrinolysis , leading to widespread deposition of fibrin in the circulatory system with inadequate fibrin removal, micro vascular thrombosis and finally multiple organ dysfunction (MOD), which is associated with poor outcome. At the same time, excessive consumption of platelets and coagulation factors may induce severe bleeding . Up to now, there is no consensus on the appropriate anticoagulant therapy of septic DIC. A number of controlled clinical trials with coagulation inhibitors have been published . In DIC no beneficial effects of heparin could be seen. In one tri...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596060</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596060</guid>        </item>
        <item>
            <title>Venous thrombo-embolism and aortic calcifications; more evidence on the link between venous and arterial thrombosis</title>
            <link>http://www.medworm.com/index.php?rid=2596059&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384808005100%2Fabstract%3Frss%3Dyes</link>
            <description>Recently, studies have shown a possible link between venous thromboembolism (VTE) and atherosclerotic disease . Although not all studies found an association , several showed a higher risk of subsequent (fatal and nonfatal) arterial thrombotic events in patients with VTE compared to healthy controls . This association seemed more pronounced in patients with unprovoked VTE . It is unknown whether patients with VTE also have an increased prevalence of calcifications of the aorta compared to controls. Calcifications of the aorta represent an advanced stage of atherosclerosis and are associated with an increased risk of future atherosclerotic events . (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596059</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596059</guid>        </item>
        <item>
            <title>Deep venous thrombosis in duplicated superficial femoral veins</title>
            <link>http://www.medworm.com/index.php?rid=2596058&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384808005434%2Fabstract%3Frss%3Dyes</link>
            <description>The human vein system has a complex embryology which causes frequent anatomic variations . As a result of vascular x-ray and surgery, in which the vascular tree can be observed, it has been demonstrated that only 1/6 patients are exempt of these anomalies. One of the most common is the duplicity of the superficial femoral vein . (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596058</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596058</guid>        </item>
        <item>
            <title>JAK2V617F mutation screening in patients with retinal vein thrombosis or recurrent fetal loss</title>
            <link>http://www.medworm.com/index.php?rid=2596057&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384808005495%2Fabstract%3Frss%3Dyes</link>
            <description>Pathophysiological mechanisms of thrombosis in unusual sites, such as splanchin veins, retinal vein and cerebral sinus, or underlying recurrent fetal loss, are poorly known. Recently, it has been shown that most patients with splanchin vein thromboses, even in the absence of overt hematological signs of an underlying myeloproliferative neoplasm (MPN) , harbor the JAK2V617F mutation . This mutation represents the commonest acquired genetic abnormality displayed by 95% of patients with polycythemia vera (PV) and 60% with essential thrombocythemia (ET) (reviewed in ). A JAK2V617F mutated genotype in ET patients represented an independent risk factors for pregnancy complications, in particular first trimester fetal loss . Owing these observations, there has been considerable interest in evalua...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596057</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596057</guid>        </item>
        <item>
            <title>First report on the effect of thrombin and factor Xa on cardiomyocytes in a three-dimensional cell culture model</title>
            <link>http://www.medworm.com/index.php?rid=2596056&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384808005525%2Fabstract%3Frss%3Dyes</link>
            <description>A common feature of acute coronary occlusion and reperfusion is the presence of high local concentrations of thrombin and other procoagulant enzymes such as factor Xa in the coronary vessels . Thrombin and factor Xa act on specific protease-activated receptors (PARs), which are present on cardiomyocytes . Activation of these receptors induces a variety of cellular responses, including changes in intracellular calcium concentration and release of inositol-triphosphate . This is the first investigation on the effect of thrombin and factor Xa in a three-dimensional (3D) biohybrid system of multicellular cardiomyocyte aggregates (spheroids) from chicken embryo hearts . (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596056</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596056</guid>        </item>
        <item>
            <title>Elevated platelet density and enhanced platelet reactivity in stable angina pectoris complicated by diabetes mellitus type II</title>
            <link>http://www.medworm.com/index.php?rid=2596055&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809000127%2Fabstract%3Frss%3Dyes</link>
            <description>This study investigates platelet reactivity in T2DM complicated by CHD. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596055</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596055</guid>        </item>
        <item>
            <title>Recombinant variant fibrinogens substituted at residues γ326Cys and γ339Cys demonstrated markedly impaired secretion of assembled fibrinogen</title>
            <link>http://www.medworm.com/index.php?rid=2596054&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001960%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The present study indicated that the 326-339 intrachain disulfide bond has a crucial role in maintaining the tertiary structure of the C-terminal domain of the γ-module, which is necessary for fibrinogen assembly and specifically secretion. A combination of the present results and observations from naturally occurring heterozygous cases of γ326Tyr and γ326Ser suggest that heterozygous fibrinogen molecules containing variant γ-chains might be secreted into plasma and show impaired fibrin polymerization, resulting in a phenotype of hypodysfibrinogenemia. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596054</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596054</guid>        </item>
        <item>
            <title>Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro</title>
            <link>http://www.medworm.com/index.php?rid=2596053&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001686%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Neoplastic cells produce procoagulants responsible for hypercoagulation states frequently observed in cancer patients. It is accepted that two major procoagulants from malignant tissue are tissue factor (TF) and a direct activator of coagulation factor X called cancer procoagulant (CP). Direct factor X-activating activity of cultured human malignant melanoma WM 115 cells has been analyzed in the cell extracts, whole cells and in the medium after the cell culture. The factor X-activating activity was detected in the malignant cell lysates but not in the cultured medium or intact malignant cells. The lysates contained no TF as determined by Western blotting and enzyme-linked immunosorbent assay (ELISA) using anti-TF monoclonal antibody. The enzymatic characteristics of the activity...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596053</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596053</guid>        </item>
        <item>
            <title>The presence of γ′ chain impairs fibrin polymerization</title>
            <link>http://www.medworm.com/index.php?rid=2596052&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384808005446%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The presence of γ′ chains slows lateral aggregation and alters fibrin structure. We suggest these changes are likely due to charge-charge repulsion, such that polymerization of the γ′/γ′ homodimer is more impaired than the heterodimer since these repulsions are partially offset by incorporation of γ chains in the γ/γ′ heterodimer. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596052</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596052</guid>        </item>
        <item>
            <title>Nitrite or sildenafil, but not BAY 41-2272, blunt acute pulmonary embolism-induced increases in circulating matrix metalloproteinase-9 and oxidative stress</title>
            <link>http://www.medworm.com/index.php?rid=2596051&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384808005598%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Introduction: Inhibition of matrix metalloproteinases (MMPs) improves the hemodynamics during acute pulmonary embolism (APE) and oxidative stress upregulates MMPs. We compared the effects of different NO-cGMP pathway activators on APE-induced increases in MMPs.Materials and Methods: Hemodynamic and biochemical evaluations were performed in non-embolized dogs treated with saline (N=5), and in microspheres embolized dogs receiving saline (n=9), or nitrite (6.75 µmol/kg i.v. over 15 min followed by 0.28 µmol/kg/min; n=5), or sildenafil (0.25 mg/kg; n=5), or BAY 41-2272 (0.03, 0.1, 0.3, and 1 mg/kg/h; n=5). Plasma thiobarbituric acid reactive substances (TBARS) concentrations were determined. Zymograms of plasma samples were performed, and in vitro antioxidant effects or inhib...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596051</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596051</guid>        </item>
        <item>
            <title>Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin</title>
            <link>http://www.medworm.com/index.php?rid=2596050&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001595%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: Background: The standardized test used for evaluating the effect of warfarin is the prothrombin time (PT) which is measured and expressed in international normalized ratio (INR). Regular control of treatment intensity is required since inappropriate dosage increases the risk for complications. Portable point-of-care analytical instruments for measurement of capillary whole blood PT have been available for the last decades. The purpose of this study was to compare and evaluate INR values obtained by the point-of-care device CoaguChek XS, to Owren PT in a hospital setting.Materials and Methods: In 397 warfarin-treated patients, capillary whole blood was analyzed with the CoaguChek XS and the results were compared to analysis of venous plasma samples with the Owren PT assay. To stud...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596050</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596050</guid>        </item>
        <item>
            <title>Comparative hemostatic parameters in BALB/c, C57BL/6 and C3H/He mice</title>
            <link>http://www.medworm.com/index.php?rid=2596049&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384808005343%2Fabstract%3Frss%3Dyes</link>
            <description>This study describes micro-methods to determine biological parameters in plasma of three strains of mice. Platelet count was significantly different among strains. C57BL/6 mice showed the highest values (988×103/μL) and BALB/c the lowest (782×103/μL). Fibrinogen levels were 2.55 (C57BL/6), 2.37 (BALB/c) and 2.28 g/L (C3H/He). Some inter-strain differences were observed in factor XIII (94, 118 and 114%) and plasminogen levels (142, 80 and 135%) in C57BL/6, BALB/c and C3H/He, respectively. Additionally, we observed individual mice factor XIII and plasminogen levels between 80 to 200% and 65 to 180%, respectively, in relation to pooled human plasma; and between 70 to 185% and 70 to 155%, respectively, against pooled mice plasma. To our knowledge, this is first report in the literature in...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596049</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596049</guid>        </item>
        <item>
            <title>Interleukin-10 correlates with oxidized low density lipoprotein in coronary culprit plaques</title>
            <link>http://www.medworm.com/index.php?rid=2596048&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001157%2Fabstract%3Frss%3Dyes</link>
            <description>Inflammation plays an important role in the pathogenesis of atherosclerosis and plaque instability . We and others have demonstrated that many pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, IL-18 and interferon-γ are expressed in human atherosclerotic plaques, and the expression levels of most of them are increased at sites of plaque rupture . However, the roles of anti-inflammatory cytokines and their localization in coronary culprit plaque have not been defined. Oxidized low density lipoprotein (ox-LDL) is also involved in the disruption of atherosclerotic plaque . Vulnerable plaques contain more significant numbers of ox-LDL-positive macrophages , which when stimulated by ox-LDL release many pro-inflammatory cytokines that contribute to plaque instability , as well a...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596048</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596048</guid>        </item>
        <item>
            <title>Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time</title>
            <link>http://www.medworm.com/index.php?rid=2596047&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384809001170%2Fabstract%3Frss%3Dyes</link>
            <description>In this study, we have investigated if GB can potentiate the antiplatelet effects of cilostazol to explore the utility of combination therapy of cilostazol and GB against peripheral occlusive vascular diseases. GB or cilostazol was evaluated alone or in combination for the antiplatelet activity using in vitro and in vivo models. In addition, potential bleeding side effect of the combinative therapy was assessed by measuring bleeding time, prothrombin time (PT) and activated partial thromboplastin time (aPTT) in vivo after oral administration. In in vitro assays using freshly isolated human platelets, the combination of cilostazol and GB showed superior inhibition of both the shear and the collagen-induced platelet aggregation to those of each drug alone. In accordance with these enhanced i...</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596047</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596047</guid>        </item>
        <item>
            <title>Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13</title>
            <link>http://www.medworm.com/index.php?rid=2596046&amp;cid=s_36108_19_f&amp;fid=36108&amp;url=http%3A%2F%2Fwww.thrombosisresearch.com%2Farticle%2FPIIS0049384808004052%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The CUB-1 domain is critical for ADAMTS-13 secretion and stability upon secretion. ADAMTS-13 deficiency found in TTP patients could be resulted from reduced ADAMTS-13 secretion and, in the case of C1213Y and K1256FS accelerated degradation. W1245del is highly resistant to degradation and active in cleaving VWF. (Source: Thrombosis Research)</description>
            <author>Thrombosis Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2596046</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2596046</guid>        </item>
    </channel>
</rss>
